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Abstract

THE IMPACT OF CHEMOTHERAPY AND RADIOTHERAPY FOR BREAST CANCER
ON COGNITION AND FUNCTIONAL PERFORMANCE: A COMPARATIVE ANALYSIS
OF SURVEY DATA TAKEN AT THREE TIME POINTS POST-TREATMENT
By Ann Marie Potter, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2017
Dissertation Chair: Tony Gentry, Ph.D. OTR/L, FAOTA,
Associate Professor, Occupational Therapy Department

Cognitive impairment related to treatment for breast cancer, affects as many as
75% of patients in study samples (Jansen, Cooper, Dodd & Miaskowski, 2011). Deficits
in the cognitive domains of short-term memory, attention, speed of information
processing, judgment, reasoning, spatial attention, and verbal memory have been
documented. The extent to which these deficits impact functional performance within
this population has not yet been quantified. The purpose of this study was to investigate
the impact of breast cancer on self-reported cognition and functional performance in the
six months post-completion in two groups of breast cancer survivors, a chemotherapy
group and chemotherapy and radiotherapy group. Cognition and functional performance
were measured with the Patient Reported Outcomes Measurement Information System
(PROMIS®). Cognition was measured in terms of abilities and concerns. Functional
performance measures addressed the constructs of physical function, ability to

participate in social roles and activities, and satisfaction with participation in social roles
and activities.
Sixteen female participants (ages 28-45) completed online surveys three weeks
following the conclusion of chemotherapy or radiotherapy and three and six months
later. Linear mixed-effects models were used to analyze changes over time within
groups and compare differences between groups. Over the six months post-treatment
the chemotherapy group had a significant improvement in physical function (p=.0178),
and the chemotherapy + radiotherapy group showed significant gains in the ability to
participate in social roles and activities (p=.0447). Fatigue was a significant factor in the
chemotherapy + radiotherapy group (p=.015). No significant differences between
groups were noted for changes in cognition, functional performance or psychosocial
factors.
This research provides insight into self-reported changes in cognition and
functional performance in the six months following breast cancer treatment. Cognition
and functional performance appear to be interrelated and impacted by a constellation of
factors that occupational therapists and oncology providers need to be aware of in order
to best support cancer survivors in the resumption of occupations after treatment. A
comprehensive approach to assessment and intervention that considers the complexity
of cognitive performance as it relates to physical capacity and concurrent symptoms is
recommended.

Chapter 1: Introduction

This chapter summarizes current research on the impact of chemotherapy and
radiotherapy on cognition and functional performance among patients with breast
cancer. An overview of the problem of post breast cancer cognitive impairment is
provided, followed by the purpose and specific aims for this study. The chapter
concludes with discussion of the study rationale and a brief introduction to the
theoretical underpinnings for this work.
Post Breast Cancer Cognitive Impairment
The relative survival rate for all stages of breast cancer in the United States is
89.5% (Howlander, et al. 2015). In response, clinicians are expanding care to include
recovery and survivorship, including attention to symptoms and sequelae related to
cancer treatment (Alfano, Ganz, Rowland & Hahn, 2012). Cognitive problems
associated with breast cancer treatment are a major concern for survivors. The
“impairment of patients’ memory, learning, concentration, reasoning, executive function,
attention, and visuospatial skills during and after the discontinuation of chemotherapy” is
commonly referred to as chemobrain or chemofog (Argyriou, Assimakopoulos,
Iconomou, Giannakopoulou & Kalafonos, 2011, p. 127). Chemotherapy induced
cognitive impairment (CICI) and chemotherapy-related cognitive impairment (CRCI) are
terms frequently used in the literature (Jansen, Cooper, Dodd & Miaskowski, 2011;
Myers, 2009). This terminology originated from early assumptions that chemotherapy is
1

the cause of treatment-related cognitive impairment. Research has demonstrated that a
variety of factors contribute to cognitive impairment, therefore I am using the term post
breast cancer cognitive impairment (PBCCI) to better capture the essence of the
phenomenon as it is now understood.
The impact of cognitive impairment on the resumption of life activities following
cancer treatment is not well quantified or understood. Current research into PBCCI
relies heavily on standardized batteries of neuropsychological tests and self-report
measures. Standardized neuropsychological testing methods often fail to adequately
address the impact of cognitive impairment on functional performance (Baddeley, 2004;
Sbordone, 1996; Wilson, 2004). Functional performance encompasses the ability to
perform activities of daily living (ADL’s), instrumental activities of daily living (IADL’s)
and social participation. Self-reports of PBCCI frequently describe decreased
functioning in these areas that neuropsychological testing fails to uncover (Nelson &
Suls, 2013).
The National Comprehensive Cancer Network’s (NCCN) guidelines for
addressing cancer-related cognitive function recommend occupational therapy as a
“first line” intervention to assist individuals experiencing specific functional limitations
related to cognitive impairments associated with any type of cancer diagnosis and
treatment (Denlinger et al., 2014). Occupational therapists are concerned with the
impact of impairment on functional performance and how participation in personally
meaningful activities can be improved. The extent to which cognitive impairment posttreatment for breast cancer impairs functional performance is not well documented. This
study utilized the Patient Reported Outcomes Measurement Information System
2

(PROMIS®) to gain a better understanding of any relationship between self-reported
cognitive abilities and cognitive concerns with functional performance experienced by
breast cancer survivors who have undergone adjuvant chemotherapy as compared to
those who have undergone both chemotherapy and radiotherapy.
Breast Cancer
Breast cancer is the most commonly diagnosed cancer among American women
and the second leading cause of cancer death. The National Cancer Institute predicted
approximately 252,710 new breast cancer diagnoses for 2017 (Howlander, et al. 2017).
Men account for 1% of breast cancer cases (Howlander, et al. 2015). There are several
different types of breast cancer: Ductal carcinoma in situ (DCIS), invasive ductal
carcinoma (IDC), lobular carcinoma in situ (LCIS), invasive lobular carcinoma (ILC) and
inflammatory breast cancer (IBC). Ductal carcinoma is the most common type of breast
cancer and begins when the linings of the milk ducts transform into abnormal cancer
cells. Lobular carcinoma begins in the lobes of the breast. In situ means the cancer is
enclosed in either the duct or lobe and has not spread to surrounding tissue. Invasive
cancer has spread into other parts of the breast tissue and possibly beyond to other
tissues in the body. Inflammatory breast cancer is a rare and aggressive form that is
caused by cancer cells blocking the lymph vessels in the skin (National Cancer Institute,
2012).
Breast cancer is staged according to the TNM classification system: (T) the size
of the primary tumor, (N) the number of regional lymph nodes where the cancer has
spread, and (M) distant spread or metastasis (NCI, 2015). DCIS and LCIS are stage 0.
Stages I-IV are summarized in Table 1.
3

Table 1
Breast Cancer Staging According to the National Cancer Institute
Stage

TNM Description

IA

T<2cm, N=0, M=0

IB

T<2cm, N=small clusters, M=0

IIA

T<2 cm, N=1-3, M=0 or
T= 2-5 cm, N=0, M=0

IIB

T=2-5 cm, N=small clusters
T=2-5cm, N=1-4, M=0
T>5cm, N=0, M=0

IIIA

N=4-9 with or without tumor or
T > 5cm, N=small clusters or
T>5cm, N=1-3, M=0

IIIB

T=any size, M=spread to chest wall and/or skin and/or N=9+

IIIC

T=with or without, N=10+ or M: in nodes above or below the collar
bone, axilla or near the breast bone

IV

M=other organs in the body

In addition to stages, breast cancer is categorized in groups based on hormone
receptor and human epidermal growth factor (HER2) status. Hormone receptor (HR)
positive (ER+/ PR+) breast cancers have receptors on the cell walls that are sensitive to
naturally occurring estrogen and progesterone. HR negative (ER-/PR-) breast cancer
does not have hormone receptors on the outside walls of the cells. The HER2 gene is a
4

growth promoting protein that helps control breast cell growth (Anderson, Rodenberg &
Katki, 2014). In breast cancer that involves the HER+ genotype, there is uncontrolled
cell division and rapid growth of cancer cells. Luminal A breast cancer is ER+ and/or
PR+ and HER2- and accounts for approximately 70% of diagnosed breast cancer
(Anderson et al., 2014). Luminal B breast cancer is ER+ and/or PR+ and HER 2+. This
is an aggressive type of cancer and accounts for approximately 10% of all breast
cancers (Anderson et al., 2014). HER2 type breast cancer is ER-/PR- and HER2 + and
makes up 5% of breast cancers (Anderson et al., 2014). Basal-like or triple negative
breast cancer (ER-/PR-/HER2-) makes up 12% of breast cancers and is more
aggressive than the Luminal A and B types (Anderson et al., 2014). These typologies,
along with tumor profiling are used to guide treatments for breast cancer.
Treatment for breast cancer may include surgery, radiation, hormone therapy,
chemotherapy and/or targeted therapy (NCI, 2015). Surgery is used for stages I-IIIA to
remove the primary tumor. Surgery may be a lumpectomy, breast conserving tumor
removal, or mastectomy. Sentinel lymph node biopsy is used in conjunction with surgery
to determine if cancerous cells have spread to the lymph system. Physical side effects
of surgery include pain, tenderness and the development of scar tissue, which may
result in limited range of motion and lymphedema. Surgery has traditionally preceded
other types of adjuvant treatment for breast cancer. Recently, preoperative or
neoadjuvant chemotherapy has come into greater use. The goal of neoadjuvant
treatment is to shrink the tumor, which may make an unresectable tumor operable or
downstage a tumor to allow for breast conservation (Schott & Hayes, 2012).
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The goal of radiation therapy is to destroy any remaining disease in the breast
tissue after surgery and prevent local recurrence. Short-term side effects of radiation
may include swelling, skin changes such as burning, and fatigue. Possible long-term
side effects of radiation are nerve damage in the arm, brachial plexopathy,
lymphedema, and damage to the lungs and heart (Meric et al., 2002). Radiation
treatment has been implicated in cognitive impairment, affecting verbal learning and
memory, delayed recall, visual perception, and visual attention (Nguyen et al., 2013;
Shibayama et al., 2014). Subsequent cognitive impairment may be related to fatigue or
induced inflammation that elevates proinflammatory cytokines (Shibayama et al. 2014).
Hormone therapy is a systemic therapy that is used with ER+ breast cancer. The
drug, Tamoxifen, works to reduce the risk for recurrence by blocking estrogen receptors
(Dalmau, Armengol-Alonso, Muñoz, & Seguí-Palmer, 2014). Side effects of tamoxifen
include blood clots and bone thinning. Aromatase inhibitors (AIs), Femara, Arimidex and
Aromasin, prevent the body from making estrogen in post-menopausal women by
blocking an enzyme in fat tissue. Side effects of AIs include muscle pain, joint stiffness
and pain. (Niravath, 2013). Hormonal treatment is recommended for five years or more.
Hormonal treatments are associated with declines in cognition, specifically in the
domains of visual and verbal memory (Bender et al., 2009). Functional impairment
related to the use of hormonal treatments is not documented in published literature.
Chemotherapy is a systemic treatment that kills fast growing cancer cells or
stops them from dividing. Chemotherapy for breast cancer often consists of a
combination of drugs given intravenously. There are five common regimes of
chemotherapy: cyclophosphamide, doxorubicin and fluorouracil (CAF),
6

cyclophosphamide and doxorubicin (AC), cyclophosphamide, doxorubicin and taxol
(AC-T), docetaxel, doxorubicin and cyclophosphamide (TAC) and taxotere or docetaxel
and cyclophosphamide (TC) (NCI, 2015). Neoadjuvant chemotherapy is administered
prior to the surgical removal of the primary tumor. Post-operative adjuvant
chemotherapy is administered after surgical removal of the primary tumor. During
chemotherapy individuals may experience hair loss, mouth sores, loss of appetite,
nausea and vomiting, and fatigue. Long-term side effects of chemotherapy may include:
menstrual changes, neuropathy, heart damage, hand-foot syndrome, decrease in
cognitive functioning and fatigue (Howell, Jones & James, 2013). Neo-adjuvant
chemotherapy is administered prior to surgery to shrink the tumor in more aggressive
forms of breast cancer (stage III-IV). Targeted chemotherapies such as Trastuzumab
and Pertuzumab block the HER-2 protein and are only used in individuals who test
HER2+. Heart damage, hand and foot syndrome and fatigue are side effects associated
with targeted chemotherapy.
Purpose
The original purpose of this study was to compare any changes in self-reported
cognition to self-reported changes in functional performance among individuals with
breast cancer following the completion of adjuvant chemotherapy or radiotherapy for
breast cancer. Due to difficulty recruiting individuals receiving only radiotherapy and to
maintain two groups for comparison, changes were made in the study design to include
individuals receiving both chemotherapy and radiotherapy. This change limits the ability
to make conclusions regarding the impact of radiation alone.
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The practical goals of this study are to offer evidence-based guidance to
occupational therapists and other clinicians who serve community dwelling breast
cancer survivors regarding the functional impairments, activity limitations and
participation restrictions that survivors face in order to develop more meaningful and
effective assessment methods and treatment plans. The original specific aims of this
survey research with the changes in italics were:
1. Measure changes in cognition for the chemotherapy and chemotherapy +
radiotherapy groups over the 6 months following the completion of treatment.
2. Compare any changes in cognition between the chemotherapy and
chemotherapy + radiotherapy groups.
3. Measure changes in functional performance for the chemotherapy and
chemotherapy + radiotherapy groups over the 6 months following the
completion of treatment.
4. Compare any changes in functional performance between the chemotherapy
and chemotherapy + radiotherapy groups.
5. Compare any changes in cognition and changes in functional performance
within each treatment group.
6. Compare any changes in cognition and changes in functional performance
between the treatment groups.
In this study, cognition was operationalized as self-reported cognitive abilities
and concerns. Functional performance was operationalized as self-reported physical
function and social participation. The study assessed cognition and functional
performance at three time points for women who have completed either chemotherapy
8

or chemotherapy + radiation therapy for breast cancer, comparing these parameters
over time within groups and between groups. Assessment occurred at the conclusion of
neoadjuvant chemotherapy (if not radiotherapy), adjuvant chemotherapy (if not
radiotherapy), or radiation and 3 and 6 months afterward. The study used the Patient
Reported Outcomes Measurement Information System (PROMIS®) to measure selfreported changes in cognition and functional performance.
The secondary aims for this study were:
7. Compare changes in cognition and functional performance with mediating
factors, including anxiety, depression, fatigue, sleep disturbance and pain
interference.
The Conceptual Model of Chemotherapy-Related Changes in Cognitive function
recognizes the complex interplay of multidimensional factors affecting cognition after
treatment (Hess & Insel, 2007). This model is addressed further in the literature review
chapter. The PROMIS-57 scales of anxiety, depression, fatigue, sleep disturbance and
pain interference were used to gather data about these mediating factors. Post-Hoc
analysis explored trends over time in cognition and functional performance.
8. Compare caregiver/significant others perceptions of cognitive impairment with
self-reports of breast cancer survivors.
Originally, I had hoped to compare subject self-ratings on the PROMIS
instrument with caregiver surveys using the Patient Competency Rating Instrument,
Caregiver Version (Wilson, 2004). This aim was not carried out. Caregiver referral was
optional in the study. Only three participants provided contact information for a
caregiver. No caregivers replied to the email invitations for the study.
9

Rationale
Cognitive impairment associated with treatment for cancer is receiving significant
attention within the literature and the oncology, rehabilitation and survivorship
communities (Denlinger, et. al., 2014; Player, Mackenzie, Willis & Loh, 2014; Wefel,
Vardy, Ahles & Schagen, 2011). The greatest attention has been directed to the
population of breast cancer survivors. The National Comprehensive Cancer Network
(NCCN) Clinical Practice Guidelines in Oncology- Survivorship: Cognitive Function
Version 1.2014 (Denlinger, et. al., 2014) recommend occupational therapy as a first line
intervention to address specific functional limitations associated with cognitive
dysfunction. Within these guidelines, the lack of screening tools for assessment is
acknowledged, and the panel recommends evaluation of cognitive impairment as a way
to guide rehabilitation efforts. This study will help to inform the oncology community
about any changes in self-reported cognition and functional performance over the sixmonth time span immediately following the completion of chemotherapy or
chemotherapy + radiotherapy for breast cancer.
Theoretical Framework
The Conceptual Model of Chemotherapy-Related Changes in Cognitive Function
developed by Hess & Insel (2007) is based on existing knowledge about cognitive
impairment associated with all types of cancer. This model defines a constellation of
factors and mediators that may lead to cognitive impairments and which result in
functional performance limitations and decreased health-related quality of life. This
model was expanded by Myers (2009) to include a greater recognition of the
interrelationships and impacts of concurrent symptoms such as fatigue, pain and
10

depression. This study was based on findings by Hess & Insel (2007) and Myers (2009)
that a confluence of factors causes PBCCI, and examined the relationship between
cognitive changes and functional performance. This relationship is not well defined
within either the original or revised model. The International Classification of
Functioning, Disability and Health Core Set for breast cancer (World Health
Organization, 2001), and the Model of Human Occupation (MOHO) (Kielhofner, 2008)
served as lenses to view the relationship between cognitive impairment and functional
performance.
Summary
PBCCI is a complex phenomenon and its true impact on functional performance
in everyday life is not well understood. This study describes and compares changes in
cognition and functional performance that may occur during the six months following the
completion of chemotherapy or chemotherapy + radiotherapy for breast cancer.
Additionally, this study compares changes in cognition following chemotherapy or
chemotherapy + radiotherapy with changes in functional performance. The influence of
mediating factors was explored. This study addresses a significant gap in the literature
regarding the consequences of changes in cognition related to breast cancer treatment
and functional performance. The study offers evidence-based insights on the impact of
PBCCI on participation in daily activities that may assist occupational therapists in
adapting assessments and interventions that will better assist breast cancer survivors in
transitioning back to life’s roles and responsibilities after treatment.

11

Chapter 2: Literature Review

Post breast cancer treatment cognitive impairment (PBCCI) is bothersome and
troubling for cancer survivors and poses a challenge to clinicians who wish to determine
the nature of its impact on everyday activity. As discussed in this chapter, PBCCI is
characterized by deficits in short-term memory, attention, speed of processing
information, judgment, reasoning, spatial perception, and verbal/nonverbal memory that
may be noted in patients who have undergone treatment for breast cancer. Current
research suggests that PBCCI negatively affects the everyday functioning of breast
cancer survivors, however, the extent of impact has not been well quantified.
This chapter provides an overview of conceptual models from the disciplines of
occupational therapy and oncology nursing that have guided the study. An overview of
PBCCI is presented, including postulates of etiology, and domains of cognition that are
impaired. Next, commonly reported cognitive sequelae and associated functional
limitations are discussed. As noted by occupational therapy researchers HartmanMaeir, Katz, and Baum (2009): “Cognition is embedded in many aspects of daily life
where the individual is required to perform complex activities, formulate goals and carry
them out effectively.” Cognitive skills are crucial in everyday living and it is important to
understand the impact of PBCCI on everyday functioning in order to develop treatment
strategies that will improve the quality of life for breast cancer survivors.

12

Theoretical Foundations
The Conceptual Model of Chemotherapy-Related Changes in Cognitive
Function.
The Conceptual Model of Chemotherapy-Related Changes in Cognitive Function
provides a means for examining “chemobrain” in regards to the relationship of
physiological and psychosocial factors (Hess & Insel, 2007). Developed in the field of
oncology nursing, the purpose of the model is to promote research into the mechanisms
of cognition that may serve as a foundation for interventions aimed at improving
cognitive functioning and overall wellbeing. This model defines two antecedents:
physiological changes resulting from the treatment of cancer and psychosocial factors
related to the experience of the diagnosis. Mediators of the physiological factors include
the specific chemotherapy drugs used in treatment, their dose and duration, other
medications taken, and radiation therapy and its associated toxicities. Psychosocial
symptoms include anxiety, stress, depression, and distress (Hess & Insel, 2007). Hess
and Insel (2007) point out that this is not an exhaustive list of symptoms. They assert
that every individual will have a unique constellation of factors that may affect cognitive
function. This model recognizes the potential impact of the following moderators or
intervening variables: age, education, intelligence, genetic factors, and coexisting
neurocognitive disorders. This model does not specifically include the impact of socioeconomic status and social supports. Hess & Insel (2007) specifically note “until the
domains of cognitive function affected by cancer treatment are identified and
instruments are used consistently to measure the domains, knowledge will not progress
concerning the prevention or treatment of the problem” (p. 991). The intention of this
13

model is to develop an understanding of the consequences of chemotherapy-related
declines in cognition in the context of health-related quality of life and functional ability.
Green, Pakenham and Gardiner (2005) proposed a model of subjective and
objective cognitive outcomes associated with cancer. The purpose of this model was to
stimulate a greater understanding of the relationships among objective and subjective
cognitive outcomes. Objective outcomes are those measured by neuropsychological
tests and subjective outcomes are based in an individual’s perceptions of their quality of
life. Cancer treatments, psychosocial factors, and physical health have direct
relationships with emotional health and objective cognitive impairment, while emotional
health and objective cognitive impairment have a direct relationship to subjective
cognitive impairment. In comparison to Hess & Insel’s (2007) work, Green et al. (2005)
provided a closer look at the relationship between the objective and subjective cognitive
differences that are reported. A major shortfall of this model is that Green et al. did not
discuss the outcomes of cognitive impairment in terms of function and health-related
quality of life.
Myers (2009) (see Figure 1) revised Hess & Insel’s (2007) model based on the
Theory of Unpleasant Symptoms. This theory describes the interactions and
relationships between physiological, psychological and situational factors on
performance in the areas of functional status, cognition and physical performance
(Myers, 2009). Functional status is similar to the concept of participation from the ICF.
Myer’s revision of the Hess and Insel model includes an acknowledgement of the
interrelationship of the timing, intensity, distress and quality of concurrent symptoms
including fatigue, pain, and depression. Additionally, Myers included situational factors
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Figure 1: The Revised Conceptual Model of Chemotherapy-Related Changes in
Cognitive Function Based on the Theory of Unpleasant Symptoms.
Note. From “ A Comparison of the Theory of Unpleasant Symptoms and the Conceptual Model of
Chemotherapy-Related Changes in Cognitive Function” by J.S. Myers, 2009, Oncology Nursing Forum,
36(1), p.E8. Copyright 2009 by the Oncology Nursing Society. Reprinted with permission.

as mediators. These include lifestyle factors, employment type and status, diet,
exercise, personal experience, marital status, and social support. While the revision
provides a more comprehensive view of the “symptom experience of cognitive
impairment” it minimizes the multidimensionality of the concurrent symptoms. Both the
original and revised model are lacking in definitions of the consequences or outcomes
of chemotherapy-related cognitive function. Radiotherapy is viewed as a mediator and
its specific role in cognitive impairment is not defined within this model. No models exist
to explain the relationship of non-CNS radiotherapy for breast cancer with cognitive
impairment. This study addresses the relationship between changes in function and the
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cognitive sequelae related to chemotherapy and chemotherapy + radiation treatment for
breast cancer. The following theoretical models provide the framework and
nomenclature for the functional consequences of PBCCI.
International Classification of Functioning, Disability and Health.
The World Health Organization’s (2001) International Classification of
Functioning, Disability and Health (ICF), and the Model of Human Occupation (MOHO)
(Kielhofner, 2008) provide a foundation for understanding how cognitive impairment
post breast cancer impacts everyday functioning. The ICF also provides a systematic
and uniform method to view the impact of cancer treatment on activities and
participation. The ICF defines impairments as problems in body function or structure
such as a significant deviation or loss. Activity is defined as the execution of a task or
action by an individual. Participation is involvement in life situations. The ICF also
considers the impact of both environmental and personal factors on an individual’s
activities and participation.
The ICF Core Set for breast cancer was validated in a study by Cooney, Galvin,
Connolly & Stokes (2013). In this study, seven focus groups of a total of 34 women with
breast cancer were utilized to confirm the ICF categories. Through these focus groups
body functions in the categories of attention, memory, perceptual functions, and vision
were identified by participants that were not included in the original breast cancer core
set. These impairments in body structure and function result in activity limitations, such
as the decreased ability to retain and make sense of verbal information and participation
restrictions including the decreased ability to engage in work activities and social
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relationships (Boykoff, Moieni & Subramanian, 2009; Jim et al., 2012; Player et al.,
2014).
The Model of Human Occupation (MOHO).
MOHO offers a holistic mechanism for viewing an individual’s function as a
person transitions through the cancer diagnosis to survivorship continuum (Kielhofner,
2008). Secondly, MOHO offers an occupation-based perspective on activities and
participation that are defined in the ICF model. Occupations are a major contributor to
quality of life. According to MOHO, at the point an individual is diagnosed with cancer
he/she commences into occupational transition. It is during this time that the individual
attempts to maintain or reestablish new activity routines. Under this model, occupations
are viewed as a product of three interrelated constructs; volition, habituation, and
performance capacity (Kielhofner, 2008).
Volition is defined as “pattern of thoughts and feelings about oneself as an actor
in one’s world which occurs as one anticipates, chooses, experiences, and interprets
what one does” (Kielhofner, 2008, p.5). Humans have an innate desire to participate in
occupations and volition encompasses the role an individual’s values play in
determining the importance of participating and performing in chosen activities.
Additionally, an individual’s sense of their capacities and effectiveness are important
motivators for participation. The volitional process is a cycle, in which an individual
makes a choice of occupation, experiences the activity, interprets the experience, and
anticipates or reacts to future potentials. The volition for occupation has been
demonstrated in a study of Icelandic women with breast cancer (Palmadottir, 2010).
Women in this study expressed fear of losing the ability to be in active control of their
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functional abilities and emotions. An emergent theme in several works is the desire for
individuals with cancer to maintain control in order to participate in activities
(Palmadottir, 2010; Sviden, G.A., Tham, K. & Borell, L. 2010).
“Habituation is defined as an internalized readiness to exhibit consistent patterns
of behavior guided by our habits and roles and fitted to the characteristics of routine
temporal, physical and social environments” (Kielhofner, 2008 p. 18). Role performance
is an important construct of habituation that may be impacted by PBCCI. The
experience of breast cancer has been demonstrated to negatively impact the roles of
parent, spouse, and worker (Boyle, 2006; Maunsell, Brisson, Dubois, Lauzier & Fraser,
1999; Shands, Lewis, Sinsheimer & Cochrane, 2006). Maintaining routines is important
to individuals with cancer and individuals become distressed when they are unable to
perform daily routines (Cheville, A. 2005: Palmadottir, 2010; Svidén, Tham & Borell,
2010). Resumption of activities of daily living and instrumental activities of daily living
are equated with a return or maintenance of normalcy (Lyons, et al. 2010, Svidén, Tham
& Borell, 2010).
Performance capacity is comprised of the physical and cognitive abilities an
individual possesses that enable him/her to do activities (Kielhofner, 2008). MOHO
values the individual’s self-perceptions of functional ability. The cognitive functions such
as memory, attention, planning, and processing speed all contribute to performance
capacity. The three constructs -- volition, habituation, and performance capacity -integrate with one another in the context of a multilayered environment to result in
human occupation that is sustained through an organized pattern. Change occurs when
an internal or external component is altered and results in a new pattern.
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The ICF is a multidisciplinary model that provides a common framework for
international collaboration and understanding of how health conditions relate to
disability, while MOHO is discipline-specific to occupational therapy (Kramer, Bowyer &
Kielhofner, 2008). Both models recognize the dynamic relationship between factors that
contribute to an individual’s ability to perform everyday activities and participate in
society. In regards to this study, the body function of cognition was studied in
association with activities and participation.
The Conceptual Model of Chemotherapy-Related Changes in Cognitive Function
and MOHO together provide a conceptual foundation for examining the impact of
PBCCI on participation in occupations. The antecedents and mediators have the
potential to significantly impact an individual’s volition, habits and performance capacity.
The physiological factors and associated toxicities result in changes to the cognitive
capacities of an individual. To understand the impact, both models call for self-report
and formal assessment of the changes. “Persons with cancer frequently gauge their
health or quality of life from an occupational perspective. They report feeling healthy or
satisfied with life when they can do activities that are important to them” (Lyons, 2006 p.
6). This sense of satisfaction is representative of occupational competence.
Occupational competence is a construct of MOHO representing an individual’s ability to
maintain routines and roles that are in line with one’s personal values resulting in
personal satisfaction (Kielhofner, 2008).
Post Breast Cancer Treatment Cognitive Impairment
The phenomenon of PBCCI is commonly referred to as “Chemobrain” or
“Chemofog”. Reports of chemotherapy-related cognitive impairment vary by type of
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cancer (Hess & Insel, 2007; Raffa 2011). Cognitive problems are more frequently
reported among breast cancer survivors than among ovarian cancer survivors (Hess &
Insel, 2007). Cognitive problems have also been reported in populations of chemotherapy treated patients with brain tumors, lung cancer, acute myeloid leukemia and
testicular cancer (Von Ah, Jansen, Allen, Schiavone & Wulff, 2011). Across cancer
types and treatments, survivors have reported cognitive problems following treatment in
the areas of complex attention, concentration, verbal and visual memory, and
processing speed. These symptoms are similar to the cognitive changes often observed
in individuals with human immuno-deficiency virus (HIV), mild traumatic brain injury,
multiple sclerosis, congestive heart failure, Type 2 diabetes mellitus, chronic obstructive
coronary disorder (COPD) and depression (Raffa 2011; Vardy, Rourke & Tannock,
2007). Breast cancer has been the primary focus of research on cancer-related
cognitive impairment (Hodgson, Hutchinson, Wilson & Nettleback, 2013; Holohan, Von
Ah, McDonald & Saykin, 2013).
Currently, there is not a consensus on the specific etiology of PBCCI. The first
published report of cognitive impairment associated with chemotherapy appeared in the
early 1980’s. Silberfarb (1983) described subtle losses in cognitive flexibility and the
ability to think abstractly, as well as problems with word finding and forgetfulness,
following chemotherapy for cancer. Initially, these symptoms were attributed to anxiety,
depression and a predisposition of age toward delirium in cancer patients, and therefore
the complaints of patients were not given much credence by physicians. Silberfarb
(1983) likened the cognitive impairment experienced by cancer patients to delirium, “a
relative global impairment of memory and thinking.” In a second report focused on
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breast cancer patients, Silberfarb (1984) hypothesized a multifactorial etiology
consisting of chemotherapy, hypercalcemia, metabolic disorders, and cerebral
metastasis. He also indicated possible roles of medications prescribed for pain,
insomnia and anxiety in causing cognitive impairment.
In 1997, van Dam et al. published a landmark study exploring cognitive function
in Dutch women with breast cancer two years after the completion of chemotherapy.
Three groups were compared, high-dose chemotherapy plus radiotherapy and
tamoxifen (n=34), standard-dose chemotherapy plus radiotherapy and tamoxifen (n=36)
and a control group (n=34) of women with stage 1 breast cancer who did not undergo
chemotherapy. Concentration and memory problems were reported by a significant
number of subjects in each treatment group (p=.006). The high dose group showed
greater cognitive impairment, higher depression scores, and lower physical function,
role function and social function scores. This study was the first to identify a correlation
between chemotherapy dosage and “chemobrain” based on the results of
neuropsychological testing.
Despite a number of succeeding studies, we still do not know the definitive cause
of cognitive changes among chemotherapy patients who have cancer (Ahles, 2012).
Many early studies made the assumption that the cause was chemotherapy alone and
did not take into consideration that most women receive additional treatments that may
include surgery with general anesthesia, radiation therapy and endocrine therapy. A
common postulate regarding the cause of “chemobrain” has been that chemotherapy
agents cross the blood brain barrier and kill brain cells (Hess & Insel, 2007; Raffa,
2011). This is unlikely, however, since common chemotherapy agents do not easily
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cross the blood-brain barrier. This has been a major problem in treating brain
metastases (Raffa, 2011). In trying to unravel what is happening in the brain to cause
cognitive problems in daily living several other postulates are currently under study.
Scientists are investigating direct neurotoxic effects, oxidative stress and DNA damage,
induced hormonal changes, immune dysregulation and release of cytokines, blood
clotting in small CNS vessels, and genetic predispositions (Ahles, 2012; The
International Cognition and Cancer Task Force, 2014). Therefore, the use of a broader
term such as PBCCI, is necessary to better describe cognitive impairment related to
breast cancer treatment.
Less is known about the role of localized (non-CNS) radiotherapy in PBCCI.
Studies of chemotherapy-related cognitive impairment using radiation groups as
comparison have shown changes in different cognitive domains unique to each group.
Nguyen et al. (2013) found the chemotherapy group to have changes in general
cognitive function, working memory, psychomotor speed and executive function with the
radiotherapy group demonstrating deficits in verbal learning, visual perception, visual
attention and short-term retention. Quesnel et al. (2009) identified changes in self-report
cognitive failures, verbal memory, and verbal fluency in the chemotherapy group, and
only verbal memory changes in the radiotherapy group. Jim et al. (2009) found attention
deficits in the radiotherapy group and impaired episodic memory in the chemotherapy
group. One hypothesis is that inflammation resulting from non-brain radiation elevates
circulating levels of pro-inflammatory cytokines which in turn are associated with
negative changes in cognition, specifically verbal memory and delayed recall
(Shibayama et al., 2014). Changes in verbal learning, visual perception, visual attention,
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and short-term retention have been noted more than ten years after the completion of
radiotherapy for breast cancer (Nguyen et al., 2013). Within the existing literature, it is
difficult to delineate changes in cognition related to breast cancer treatment due to the
lack of consistency in the domains of cognition that are measured.
An inductive process has been used to identify other contributors to PBCCI,
suggesting that fatigue, depression, anxiety and hormonal changes may play either a
causative or confounding role in PBCCI. Vearncombe et al. (2009) studied predictors of
cognitive decline in 136 Australian women diagnosed with breast cancer and treated
with chemotherapy and a control group of 21 women diagnosed with breast cancer that
did not receive chemotherapy. The subjects in the chemotherapy group were tested
prior to chemotherapy and one month post-chemotherapy. Of the chemotherapy group,
16.9% showed cognitive decline in cognition 4 weeks post conclusion of chemotherapy.
Declines in hemoglobin levels and increases in anxiety significantly correlated with
multiple test impairment, a decline on two or more cognitive measures within the
chemotherapy group. Jansen, Cooper, Dodd and Miaskowski (2011) reported similar
findings in regards to a significant decrease in hemoglobin levels in a longitudinal study
of 71 women undergoing a chemotherapy regime of AC (standard dose doxorubicin and
cyclophosphamide) or AC+T (standard dose doxorubicin and cyclophosphamide +
taxane). Significant increases were also noted in depression and fatigue scores, as well
as decreases in subjects’ self-perception of cognitive functioning. Self-reported
cognition was significantly associated with anxiety (p<0.001), depression (p<0.001) and
fatigue (p<0.001) using within subject analysis. Bender et al. (2009) concluded that
depression was a covariate as women who indicated greater depressive
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symptomatology self-reported more cognitive problems. Biglia et al. (2011) found that
higher levels of anxiety and depression were correlated with lower self-reported
cognition measured on the Functional Assessment of Cancer Therapy Cognitive Scale
(Fact-Cog 2).
In regards to hormonal treatments and menopausal status, verbal memory
impairments were noted in breast cancer survivors treated with anti-estrogens
(tamoxifen, anastrozole or combined treatment) when compared with healthy controls
(Jenkins et al. 2004). Bender et al. (2006) found that chemotherapy and tamoxifen
combined treatment resulted in greater declines in visual and verbal memory in the year
following treatment than in a chemotherapy only group. The subjects in the treatment
groups of this study were all pre- or peri-menopausal while the non-treatment group did
include women in menopause. Menopausal status differences may have skewed
Bender et al.’s results as Jenkins et al. (2006) reported, in their 3-year prospective study
of women with breast cancer in the UK, those who experienced treatment-induced
menopause were at more risk for cognitive decline. This is an important finding as these
women were younger and more likely to be dealing with different life tasks and roles
than women who were post-menopausal.
In contrast, Hedayati, Alinaghizadeh, Schedin, Nyman and Albertson’s (2012)
prospective study found significantly lower memory scores for a chemotherapy group
(n=18) but not for a hormone therapy group (n=45) when compared to a healthy control.
It is difficult to determine if the changes are related to menopause status or hormonal
treatment or both, as Bender et al.’s (2006) study included premenopausal women,
Jenkins et al.’s (2006) study included both premenopausal and menopausal subjects
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and Hedayati et al.’s sample consisted primarily of women who were in menopause.
These studies support a confounding but not a definitive role for hormonal treatments
and/or hormonal status in PBCCI. Menopausal status and the use of hormonal
treatments were tracked in this study and analyzed as a covariant.
Cognition and Breast Cancer
Changes associated with chemotherapy.
The following domains of cognitive function -- attention, memory, concentration,
intelligence, verbal ability, psychomotor function, executive function and spatial ability -have been assessed to determine levels of cognitive impairment associated with breast
and other types of cancers (Falleti, Sanfillipo, Maruff, Weih & Phillips, 2005; Hess &
Insel, 2007; Jim et al., 2012). Memory declines have been associated with
chemotherapy treatment (Bender et al., 2006; Collins et al. 2013; Ganz et al., 2013; Jim
et al., 2009; Mehnert et al., 2007; Nguyen et al., 2013; Quesnel et al. 2009). Working
memory deficits in chemotherapy groups were identified in multiple studies (Collins et
al., 2013; Mehnert et al., 2007; Nguyen et al., 2013). Declines in the domain of verbal
memory were reported by Bender et al. (2006) and Quesnel et al. (2009). Jim et al.
(2009) report problems in the domain of episodic memory. Several studies have noted
general cognitive decline and self-reports of cognitive dysfunction among subjects who
have had chemotherapy (Collins et al., 2013; Ganz et al., 2013; Jenkins et al., 2006;
Mehnert et al., 2006; Nguyen et al., 2013; Quesnel et al., 2009). Combined
chemotherapy and radiotherapy treatment has been associated with changes in
executive functioning, processing speed, subjective memory complaints and mental
fatigue (Ganz et al., 2013; Phillips et al., 2012).
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A pair of meta-analyses have examined the severity and nature of cognitive
findings for individuals with breast cancer treated with chemotherapy. Falleti et al.
(2005) analyzed 6 breast cancer studies in order to estimate the magnitude of changes
in attention, motor function, memory, executive function, language and spatial ability.
Effect sizes were calculated for each domain, with a negative effect size indicating lower
performance in the chemotherapy group compared to controls. The effect sizes ranged
from small (0.2) to moderate (0.5) with average effect sizes of -0.03 for attention, -0.051
for motor function, -0.26 for memory, -0.18 for executive function, -0.041 for language
and -0.48 for spatial ability. There were significant associations between larger effect
sizes across all domains and a shorter time since the culmination of chemotherapy,
treatment with tamoxifen and younger patient age. The overall results of this metaanalysis suggest mild cognitive impairment (Falleti et al., 2005).
Jim et al. (2012) focused their meta-analysis on long-term changes in cognitive
functioning experienced by breast cancer survivors. This meta-analysis included 17
studies, 4 that were included by Falleti et al. (2005) and the remainder which were
published after 2004. Sixty-nine neuropsychological tests were utilized across the
included studies and were categorized into eight domains: attention, executive
functioning, information processing, motor speed, verbal ability, verbal memory, visual
memory and visuo-spatial ability. Subjects in the chemotherapy groups demonstrated
significantly worse functioning in the domains of verbal ability (g -0.19) and visuospatial
ability (g -0.27) in comparison to controls and pre-chemotherapy baselines. Overall the
magnitude of effect sizes across domains was small. This study suggests that cognitive
impairment associated with breast cancer is slight. In contrast with Falleti et al. (2005),
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there were not significant impairments in motor function, memory and executive
function.
The meta-analyses discussed here are limited by the quality of the studies
included, the wide variety of assessments used and small sample sizes that ranged
from 18-97 subjects in chemotherapy groups. Additionally, there was no way to account
for confounding variables, such as depression and anxiety. Jim et al. (2012) note that
the longitudinal studies included in their meta-analysis may not have uncovered
possible changes in cognitive functioning due to practice effects. Age, education, time
since education and endocrine therapy were not associated with worse cognitive
functioning by Jim et al. (2012), unlike the results of Falleti et al. (2005).
Changes associated with radiotherapy.
Changes in verbal memory, verbal learning, visual perception, visual attention,
and executive functioning are associated with non-CNS radiation treatment for breast
cancer (Jim et al., 2009; Nguyen et al., 2013; Phillips et al., 2012; Quesnel et al., 2009).
These changes have been identified in studies in which a disease control of participants
who received only radiotherapy was used for comparison to a chemotherapy group.
Shibayama et al. (2014) set out to specifically examine changes in memory associated
with radiation treatment. They identified lower levels of verbal memory and delayed
recall in the radiation group when compared to a non-radiation group. A major limitation
of this study was that approximately 50% of the radiation and non-radiation group had
received chemotherapy and this was not controlled for in statistical analysis. Verbal
learning, visual perception, visual attention and short-term retention were identified as
long-term problems (greater than 10 years) in a radiation only breast cancer treatment
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group when compared to women who had received chemotherapy and a non-cancer
control group (Nguyen et al., 2013). These problems persisted when age was controlled
for. This study did not control for endocrine therapy, which has been identified as a
confounding factor in other studies. Moderate levels of attentional fatigue and a
decreased capacity to direct attention as measured by self-report were found to persist
over the course of radiotherapy extending out to 4 months after the conclusion of
treatment (Merriman et al., 2010). These studies demonstrate a confounding role for
radiotherapy in PBCCI, however none of these studies explored the impact of these
cognitive problems on everyday activities and social participation.
Changes in Functional Performance Associated with Breast Cancer
Breast cancer treatment may cause a number of functional performance changes
either aside from or in addition to cognitive changes. Functional performance includes
changes in physical function and the performance of ADL’s, IADL’s, as well as social
participation. In a systematic review of the literature, Ewertz and Jensen (2011)
categorized problems associated with breast cancer treatment into three areas; focal
problems, systemic problems, and psychosocial problems. Focal problems are related
to therapies such as surgery and radiation. Lymphedema, pain and other arm and
shoulder problems are included in this category. Systemic problems are attributed to the
toxicities of chemotherapy and the side effects of endocrine treatment. Neuropathy,
infertility, premature menopause and cardiovascular disease are common long-term
systematic problems associated with breast cancer treatment (Ewertz & Jensen, 2011).
Limited evidence is available about cancer-related neuropathy; however neuropathy is
related to pain and sensory and motor impairment (Brearley et al., 2011, Ewertz &
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Jensen, 2010). Evidence shows that chemotherapy treatment with a taxane produced
deficits in motor function which were hypothesized as a result of peripheral neuropathy
(Jansen, Cooper, Dodd & Miaskowski, 2011). Ewertz and Jensen (2011) delineate
psychosocial problems as consequences of diagnosis and treatment, including
depression, fear of recurrence, sleep disturbance, cognitive problems, fatigue, and
sexual problems.
Reduced arm function related to breast cancer surgery and radiotherapy has
been linked to difficulties in performance of ADL’s and a lower health-related quality of
life (Hayes et al., 2012). O’Toole et al. (2015) studied breast cancer related
lymphedema’s impact on the ability to perform upper extremity activities of daily living.
Their study followed 324 women who underwent unilateral mastectomy for
approximately 30 months after surgery, finding lower functional scores, averaged from
19 items from the DASH, associated with fear of lymphedema, pain, mastectomy and
axillary node dissection. Fatigue has also been shown to impact daily living activities for
women with breast cancer during treatment up to twelve weeks afterward (de Jong,
Candel, Schouten, Abu-Saad & Courtens, 2006). This study of 157 women with breast
cancer showed that for women who had mastectomies, lower levels of activities were
correlated with greater levels of fatigue. This was not observed in the group who had
lumpectomies. Both of these studies calculated scores for function, but they did not
account for the involvement of multiple factors related to treatment such as anxiety,
depression and pain.
It is clear that surgical treatment for breast cancer can result in upper extremity
physical impairments. These physical impairments include reduced upper extremity
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range of motion and lymphedema. Pain and fatigue also contribute to reducing the
ability to perform activities and maintaining social participation. The changes in upper
extremity function may play a confounding role in measuring the cognitive domain of
psychomotor speed as the tests that are used are typically pegboard tasks that require
fine motor skills.
Current literature does not specifically correlate functional performance problems
post breast cancer with PBCCI. However, cognitive skills are needed in order to
successfully perform most everyday activities. Ogilvy, Livingstone and Prue (2008)
identified problems in the areas of food preparation, household chores, social activities
and employment related to fatigue. This study did not examine the role of changes in
cognition as it relates to activities and participation. Braithwaite et al. (2010) report that
the presence of functional limitations post breast cancer treatment results in a
decreased overall survival. Braithwaite did not address cognitive impairment in relation
to functional limitations. Loss of functional independence is also a concern for women
experiencing PBCCI, including the inability to participate in family activities and
frustrations at work due to problems in reading, anxiety and memory problems (Player,
et al., 2014).
Changes in Functional Performance Associated with Cognition
Several studies looking at breast cancer and work provide insight into the
challenges attributed to changes in cognition. In a qualitative study of 74 breast cancer
survivors, Boykoff, Moieni and Subramanian (2009) describe PBCCI in terms of difficulty
digesting new information, decreased focus, concentration and speed. The participants
reported that decreased focus led to difficulty with job performance. Similar issues at
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work were reported in a qualitative study of 22 breast cancer survivors by Von Ah et al.
(2013). This study identified issues in the domains of short-term memory, long-term
memory, speed of processing, attention and concentration, language and executive
functioning. Participants reported that they had to work harder and utilize compensatory
strategies at work. Additionally, participants reported that they did not notice the extent
of their cognitive issues until after the completion of chemotherapy. The deficits for 16 of
22 participants did not improve over time (Von Ah et al., 2013).
Decreased self-confidence at work resulting from problems with memory were
identified by Munir et al. (2011) through their qualitative interviews of 31 breast cancer
survivors. These qualitative studies demonstrate that women may have difficulty in work
performance related to PBCCI. No existing literature was located describing the impact
of cognitive impairments related to non-CNS radiotherapy for breast cancer and
functional abilities. This study is the first to specifically focus on the relationship of
changes in cognitive abilities associated with chemotherapy and radiotherapy treatment
for breast cancer with changes in everyday functional performance.
Conclusion
The impact of PBCCI on activities and participation is not well understood. The
majority of existing research has focused on establishing evidence for the changes
through neuropsychological assessment and determining the etiology as it is related to
physiologic mechanisms. Several major issues are noted in the literature:
•

A working definition of cognitive function does not exist in relationship to cancer;

•

There is not a standardized diagnostic criteria for cancer related cognitive
impairment;
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•

Current research focuses on different cognitive domains such as language,
attention, processing, memory and concentration but not the impact on functional
performance (Hess & Insel, 2007; Raffa, 2011; Von Ah et al., 2011).
Occupational therapists specialize in enabling individuals to perform personally

meaningful occupations. Current literature points to functional limitations resulting from
PBCCI. However, these limitations have not been well quantified. Additionally, PBCCI is
most often associated with chemotherapy. Individuals who have been treated with nonCNS radiotherapy are also experiencing symptoms of PBCCI. This study measured
self-report changes in cognitive abilities and concerns, functional abilities and social
participation over 6 months following the completion of chemotherapy or chemotherapy
+ radiotherapy for breast cancer. This study also examined the impact of confounding
factors such as age, menopausal status, sleep disturbance, pain interference, anxiety
and depression on functional ability and social participation. A better understanding of
the functional impact of PBCCI may be useful in designing more effective interventions
and facilitating optimal performance of occupations by breast cancer survivors.
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Chapter Three: Research Methodology

This study, as original proposed, aimed to compare self-reported cognitive
function and everyday functional performance between two samples of patients with
breast cancer who have received either adjuvant chemotherapy or radiotherapy,
measured at the conclusion of treatment and 3 and 6 months later. Several months into
participant accrual, no individuals receiving radiotherapy had enrolled. The dissertation
committee was reconvened and approved the addition of a chemotherapy + radiation
group. Therefore the two samples consist of individuals receiving only chemotherapy or
those receiving chemotherapy + radiotherapy. The data from this study describe and
measure changes in the domains of cognitive function and everyday functional
performance over time in order to improve the predictive value of cognitive and
functional screens in guiding occupational therapy interventions for this population. This
study provides a better understanding of the extent to which PBCCI impacts the ability
to perform daily activities, which thus far has not been well documented in published
literature. This chapter describes the rationale, design, participant population,
measurement tools, procedures, and data analysis plan. Chapter four provides an in
depth description of challenges faced in recruitment and the changes made to the study
to address the problems.
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Approval
The original research plan was submitted and approved by the Massey Cancer
Center Protocol Review and Monitoring Committee Cancer Prevention and Control
Subcommittee in January 2016 (MCC-15-12217). The study (HM20006120) was
approved by the Institutional Review Boards of Virginia Commonwealth University by
expedited review according to 45 CFR 46.110 on 3/31/2017 under Expedited category
7. In April 2016, the study was approved by Exempt review through the Elizabethtown
College Institutional Review Board. In August 2016 an amendment was approved to use
Facebook for study recruitment, change eligibility requirements and to add a
chemotherapy + radiation therapy group to the study. The rationale for these changes
will be discussed later in the chapter. In February 2017 the study approved for
continuation according to 45 CFR 46.108(b) and 45 CFR 46.109(e) and 45 CFR 46.110
by VCU IRB Panel A.
Design Rationale
The Revised Conceptual Model of Chemotherapy-Related Change in Cognitive
Function provides the foundation for this study. In summary, this model views Post
Breast Cancer Cognitive Impairment (PBCCI) resulting from two primary antecedents,
cancer treatment and cancer diagnosis (Myers, 2009; Hess, 2010). The two types of
breast cancer treatment compared in this study include completion of surgery, and
either chemotherapy or chemotherapy + radiotherapy. This conceptual model goes on
to view changes in functional abilities and health-related quality of life as consequences
of changes in cognitive function (Hess, 2010; Myers, 2009). The changes in cognition
and everyday functional performance are of particular concern to occupational
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therapists, as treatment would focus on a compensatory or remedial approach to
restore functional abilities.
Recommendations from the National Comprehensive Cancer Network (NCCN)
Clinical Practice Guidelines in Oncology - Survivorship: Cognitive Function Version
1.2014 (Denlinger, et. al., 2014) and the International Cognition and Cancer Task Force
(ICCTF) (Wefel, et al., 2011) are also integrated in this study design. The NCCN clinical
practice guidelines (Denlinger, et al., 2014) cite occupational therapy as a first line
intervention for cancer related cognitive impairment, along with neuropsychology.
Occupational therapy typically addresses the ability to perform activities of interest in
daily life, and the impact of underlying client factors, in this case cognition (American
Occupational Therapy Association, 2014). This study examined the functional
consequences of Post Breast Cancer Cognitive Impairment (PBCCI) through the use of
the PROMIS Cancer Physical Function Scale, Ability to Participate Scale, and
Satisfaction with Participation Scale. The ICCTF guidelines recommend a disease
specific comparison group to control for the relative effects of the combination of
treatments that are administered for breast cancer (Wefel et al., 2011).
In the original study proposal the radiotherapy group acted as the specific
comparison group. A chemotherapy + radiotherapy treatment group was substituted to
ensure that there would be a comparison group, as it was difficult to identify and recruit
individuals receiving only radiotherapy. Nine individuals who were treated with only
radiation entered the study. None qualified due to completing their course of treatment
outside of the study parameters of the past 21 days. The study used a posttest-only
design with nonequivalent groups (O’Farrell, et al., 2013; Shadish, Cook & Campbell,
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2002). Both groups consisted of women who were diagnosed with breast cancer. One
group consisted of those who had been treated with chemotherapy, and the other group
consisted of those who had been treated with chemotherapy + radiotherapy.
Functional performance is defined in this study as performance of activities of
daily living (ADL’s) and instrumental activities of daily living (IADL’s), including social
participation and roles. The impact of the performance of roles in the areas of family and
work has been recently highlighted as a major issue for survivors of breast cancer as it
relates to cognitive impairment and an individual’s ability to resume her/his prior lifestyle
(Player et al., 2014). Therefore, the inclusion of the PROMIS Participation scales
address role performance and satisfaction, in the areas of relationships, parenting,
leisure and work (Bode, Hahn, DeVellis & Cella, 2010). This is also consistent with the
Model of Human Occupation and the construct of habituation, as discussed in Chapter
Two.
Within the Revised Conceptual Model of Chemotherapy-Related Changes in
Cognitive Function, changes in cognition and functional performance are impacted by
the interplay of lifestyle factors, situation factors and concurrent symptoms. These
factors and symptoms include age, educational level, fatigue, anxiety, depression, sleep
quality and hormonal status, all of which were measured for study participants. The
PROMIS 57 v.2 measured self-reports of anxiety, depression, pain, and sleep
disturbance at each observation. The demographic questionnaire collected related
information about age, stage of cancer, treatment, employment, educational level and
comorbidities.
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The original study proposal included a caregiver observation to provide additional
insight into changes in functional ability and participation experienced after
chemotherapy or radiotherapy for breast cancer, because awareness of cognitive
function may be over- or under-estimated when an individual has cognitive impairment
(Kolakowsky-Hayner, 2010). Providing a referral to a caregiver for participation was
optional. No caregivers entered the study, so no data is available for comparison.
Study Design
This descriptive study used a longitudinal posttest-only design at three
assessment time points with nonequivalent groups (Shadish, Cook & Campbell, 2002).
The intent of this study was to explore the relationship between changes in self-reported
cognitive abilities and cognitive concerns with changes in functional performance to
better understand the phenomenon of PBCCI for breast cancer survivors who have
completed either chemotherapy or radiotherapy. No individuals with radiotherapy
enrolled in the study. The results compare a chemotherapy only group with a
chemotherapy + radiation group. Participants in both groups were assessed at three
time points, O1: at the completion of chemotherapy or radiotherapy (within 2-3 weeks to
allow for recovery from immediate treatment effects) as a baseline, O 2 : 3 months post,
and O 3: 6 months post, in order to assess changes in cognition and function over time.
Figure 2 provides an overview of the study flow for participants. This approach mirrors
the common progression of clinical practice in occupational therapy, where a client’s
level of function is evaluated upon referral, not prior to receiving treatment for cancer.
Additionally, these time frames match with medical oncology follow-ups. Analysis of the
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Informed Consent
Eligibility Questionnaire

Observation 1
3 weeks post completion of
treatment
Demographics
PROMIS

Observation 2
3 months post completion
of treatment
Demographic Update
PROMIS

Observation 3
6 Months post completion
of treatment
Demographic Update
PROMIS

Figure 2: Study flow for participants beginning with enrollment.

resulting data from each time point may help inform medical and rehabilitation providers
of areas to be addressed with this population at common follow-up time points.
Participants completed informed consent, demographics questionnaire, the
PROMIS-57v2, the PROMIS Cognitive Abilities and Concerns Scales v1.0, PROMIS
Cancer Physical Function Scale V1.0, PROMIS Ability to Participate in Social Roles and
Activities (v2.0) and Satisfaction with Social Roles and Activities (v2.0) (See Appendix
A-C) at O1. Subsequently, at the next two observations participants completed the same
battery with a demographics update form.
Determination of Variables
Type of treatment, chemotherapy or chemotherapy + radiotherapy, is the
independent variable (IV) for comparison between groups in relationship to the
dependent or outcome variables. In regards to the complexity of PBCCI, the
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constellation of breast cancer treatment factors is the IV or predictor variable in this
study for within subject analysis. This constellation includes type of surgery, physiologic
factors including type of chemotherapy agent, radiotherapy, hormonal status, and
psychological factors including depression, anxiety, sleep disturbance, fatigue, and pain
interference as defined by the Revised Conceptual Model of Chemotherapy-Related
Changes in Cognitive Function (Myers, 2009).
Cognitive function is a dependent variable for between and within group analysis.
Cognitive function is measured in two ways, self-report assessment of cognitive abilities
and self-report assessment of cognitive concerns via the PROMIS Applied Cognition Abilities and the PROMIS Applied Cognition Concerns scales. These scales measure
perceived functional abilities and concerns in the context of everyday activities, and the
cognitive domains of memory, concentration, following directions, and learning.
Functional performance is a dependent variable comprised of measures of physical
function and social participation.
Physical function is measured by the score on the PROMIS Cancer Physical
Function scale v1.0. This scale contains questions about mobility, activities of daily
living and instrumental activities of daily living. This scale measures an individual’s selfreports of their ability to perform specific activities and is not an observation of actual
performance. The instrument is designed for use with any type of cancer diagnosis
(PROMIS, 2015a). Two aspects of the dependent variable of participation, ability and
satisfaction, were measured, using the PROMIS Ability to Participate in Social Roles
and Activities V2.0 and the Satisfaction with Roles and Activities V 2.0. These scales
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measure aspects of role performance in the areas of work, family life, friendships and
other personal responsibilities.
Covariates include depression, anxiety, sleep disturbance, fatigue, and pain
interference as measured by the PROMIS 57 Profile V2. Additional covariates including
age, educational status, work status, stage of cancer, type of surgical intervention,
concurrent treatments of hormonal, and/or targeted therapies, and lymphedema. These
were measured through self-report on the demographics questionnaire. These
covariates or moderators are included in the Revised Conceptual Model of
Chemotherapy-Related Changes in Cognitive Function (Myers, 2009).
Measures
An enrollment questionnaire and demographics measure was created for this
study (Appendix B). The collection of age, race and ethnicity follow current NIH
guidelines. The demographics measure collected information on current employment
status, caregiver status, menopausal status, stage of cancer including tumor size,
number of positive lymph nodes, and metastasis, type of chemotherapy, type of surgery
for breast cancer, tumor receptor status, and type of lymph node dissection, presence of
lymphedema, radiotherapy, targeted therapy, and medical history including, anemia,
thyroid disease, and vitamin D deficiency. The collection of demographics was based on
factors included in Myers (2009) Revised Conceptual Model of Chemotherapy-Related
Changes in Cognitive Function.
The Patient Reported Outcomes Measurement Information System (PROMIS®)
is a measure of health domains that can be utilized universally across different disease
types. PROMIS® (PROMIS, 2015b) consists of banks of questions on physical, social
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and mental health domains. The system is designed to provide a technological
infrastructure that supports NIH-funded clinical investigations across Institutes,
disciplines, diseases and subpopulations. PROMIS® instruments were developed using
Item Response Theory (IRT) “a family of statistical models that link individual items to a
presumed underlying trait or concept represented by all items in the item bank.
(PROMIS, 2015 c).
This study utilized the PROMIS v 1.0 Applied Cognition – Abilities and General
Concerns scales, the Ability to Participate in Social Roles and Activities v 2.0,
Satisfaction with Social Roles and Activities v 2.0, and the Physical Function Ca Bank, v
1.1 and the PROMIS-57 Profile v2.0 (Appendix C). For all the PROMIS® scales the raw
scores are converted to a standardized T-score for each subject. A T-score has a mean
of 50 and a standard deviation of 10. The development of the PROMIS® scales
specified procedures to ensure construct, concurrent and, criterion validity (PROMIS,
2013).
The PROMIS Applied Cognitive Abilities v1.0 and the PROMIS Applied Cognitive
General Concerns v1.0 (Appendix C) were used as the self-report measure of cognition.
The abilities scale is positively worded and asks the respondent to rate items about
attention, memory, concentration and other cognitive tasks for the past 7 days on a
scale of not at all, a little bit, somewhat, quite a bit and very much. The concerns scale
is negatively worded or problem focused asking the respondent to rate difficulty or
trouble with the same tasks on abilities scale. The questions are rated on a scale of
never, rarely (once), sometimes (two or three times), often (about once a day) or very
often (several times a day). Both scales place the cognitive domain within the context of
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an everyday activity (PROMIS, 2015d). For example, new learning is represented as an
ability in the item “I have been able to learn new things easily, like telephone numbers
or instructions. The concerns scale has the question worded “I have trouble
remembering new information, like phone numbers or simple instructions.” These scales
are based on the Functional Assessment of Cancer Therapy-Cognitive Function scale
(FACT-Cog) that was designed to measure both abilities and concerns (Lai, et al.,
2014). The PROMIS instruments were designed “to better understand cognitive function
during and following cancer treatment from a patient’s perspective” (Lai, et al., 2014).
These scales were developed with a sample of 509 participants. Items were generated
through interviews and field testing. Conceptual models were tested using
unidimensional and multidimensional item response theory. Results showed “separation
in the clusters of factor loadings between concerns and abilities to support separate
reporting of concerns and abilities” (Lai, et al., 2014). This was confirmed in the
cognitive interviewing process of the instrument development. As such, this study used
the conservative approach advocated by Lai, et al. and measured both concerns and
abilities.
Reliability and validity of the PROMIS cognitive scales has been assessed with
individuals with multiple sclerosis, revealing high internal consistency with a reliability
Cronbach α coefficient of .97 (Becker, Stuifbergen, Lee & Kullberg, 2014). Becker, et al.
(2014) also found participants who were unemployed due to their disabilities reported
lower cognitive abilities and greater concerns. This study measured both abilities and
concerns related to cognition in order to get a fuller picture of the experiences of
participants and any changes over the 6-month study period.
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The PROMIS-Ca Physical Function Scale (Appendix C) was used to measure
activities of daily living and instrumental activities of daily living. The participant rates
their level of difficulty on each item from “no difficulty” to “unable to do”. The instrument
covers activities inside and outside the home, including dressing, bathing, shopping,
laundry, doing dishes and other household tasks as well as getting in and out of a car,
traveling overnight and participation in sports. The adult cancer instrument was
developed for use with any type of cancer diagnosis. This scale contains 45 items as
compared to 38 in the general physical function scale (PROMIS, 2014a). Internal
consistency for the 38 item general physical function scale is high with a Cronbach α of
.99 (PROMIS, 2014a). The additional items on the cancer scale were developed by
content experts to address items that may convey a different meaning to individuals with
cancer and then calibrated with adult cancer patients (PROMIS, 2014a). The T-score of
50 on this scale represents the norm of the calibration sample, not the national sample
as other PROMIS scales do (PROMIS, 2014a). This instrument addresses the MOHO
construct of performance capacity.
The Ability to Participate in Social Roles and Activity scale (Appendix C)
measures perspectives about the ability to perform roles in work, family and social
environment (Bode, et al., 2010). The Satisfaction with Social Roles and Activity scale
(Appendix C) looks at how well the individual is satisfied with the performance of family,
work and social roles. For example, the abilities scale has the participant rate ability
items such as: “I have trouble doing my regular daily work around the house, I have
trouble meeting the needs of my family.” These items are rated as never, rarely,
sometimes, usually and always. The satisfaction scale has the participant rate “I am
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satisfied with my current level of family activities and I am satisfied with how much work
I can do (include work at home).” This scale addresses the MOHO constructs of
habituation and role performance. The internal consistency of both scales is high with a
Cronbach α of .99 (PROMIS, 2015e). These scales were calibrated with a sample that
included more individuals with chronic illnesses, therefore, they do not reflect the
average of the United States general population as many of the other PROMIS scales
do (PROMIS, 2014e).
The PROMIS-57 v2 scale (Appendix C) contains short form scales for anxiety,
depression, fatigue, pain interference and intensity, physical function, sleep disturbance
and the ability to participate in social roles and activities. This profile instrument includes
“high information items” that have been ranked through Computer Adapted Testing
(CAT) simulations and reviewed by content experts. The PROMIS-57 v2 is administered
as short forms that “enable a more direct comparability across people or time”
(PROMIS, 2015f). The anxiety scale asks how often, never, rarely, sometimes, often
and always, in the past seven days a participant has experienced related feelings of
worry, fear and uneasiness. The depression, fatigue, sleep disturbance, ability to
participate in social roles and activities and pain interference use the same rating
procedure. The physical function questions ask the participant to rate how difficult tasks
such as walking and doing chores are and to rate their limitations on doing house work
activities. The physical function scale of the PROMIS- 57 has overlapping items with the
PROMIS-Ca Physical Function Scale. The PROMIS-Ca Physical Function Scale is used
for analysis since it was developed with a population of individuals diagnosed with
cancer. The computer administration was set up to avoid having participants answer
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items more than once as there is overlap of the PROMIS 57 scales with the other scales
being administered.
Hypotheses
The original purpose of this study was to examine changes in self-report
cognition and everyday functional ability, as measured at three evenly spaced time
points over the first six months after the completion of either adjuvant chemotherapy or
radiotherapy for individuals with breast cancer. Due to challenges to enrollment, the
study compares chemotherapy only to chemotherapy + radiotherapy groups. Study
research hypotheses include:
HA 1: Cognition, as measured by the PROMIS Applied Cognition abilities and
concerns scales, will improve within each group across the three measurement time
points.
HA 2: Functional performance as measured by the PROMIS Cancer Physical
Function Scale, the PROMIS Ability to Participate Scale, and the PROMIS
Satisfaction with Social Roles and Activities will improve within each group across
the three measurement time points.
HA 3 : Change in cognition will positively correlate with change in functional
performance within each group.
HA 4: Cognition, as measured by the PROMIS Applied Cognition abilities and
concerns scales will differ between the chemotherapy and chemotherapy +
radiotherapy groups.
HA 5: Functional performance as measured by the PROMIS Cancer Physical
Function Scale, the PROMIS Ability to Participate Scale, and the PROMIS
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Satisfaction with Social Roles and Activities will differ between the chemotherapy
and chemotherapy + radiotherapy groups.
Participants
Individuals diagnosed with Stage I-IIIa breast cancer were recruited for the
originally proposed groups, adjuvant chemotherapy and radiotherapy. In August 2016
recruitment was expanded to include individuals receiving both chemotherapy and
radiotherapy. At this point in the progression of treatment the participants were eligible if
they were receiving targeted therapies such as Herceptin, and/ or hormonal treatments
(i.e. aromatase inhibitors or Tamoxifen). Although, concurrent treatments have been
implicated in the constellation of causes for PBCCI, excluding individuals with
concurrent treatments would have significantly decreased the ability to recruit subjects.
Eligibility
In order for a person to participate in this study he or she must have been 18
years or older, diagnosed with breast cancer stages I-IIIa and nearing the end of either
chemotherapy or radiotherapy. The original eligibility criteria was limited to having
undergone surgical intervention (mastectomy or lumpectomy) prior to adjuvant
chemotherapy. To improve accrual, the eligibility was changed to allow for neoadjuvant
chemotherapy with surgery at a later time. Anthracycline/taxane-based adjuvant
chemotherapy was required for participation. Limiting subjects to an
anthracycline/taxane-based treatment reflects current oncology practice and helped
eliminate variability due to type of chemotherapy. Subjects in the chemotherapy +
radiotherapy group must have completed a fully prescribed course of radiation
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treatment. Participants needed to understand and communicate in English at a level to
access and complete the PROMIS and demographic questionnaires.
Exclusion criteria included a diagnosis of Stage IIIB or 4 breast cancer, nonanthracycline/taxane chemotherapy regimens, a history of chemotherapy for any other
type of cancer, a history of cognitive impairment related to a brain injury, stroke,
dementia, epilepsy or a current or past disorder/ disease of the central nervous system,
a history of substance abuse, presence of a developmental disorder impacting
cognition, or a history of hospitalization for mental illness. Individuals with stage IIIb or 4
breast cancer were not eligible, as they are more likely to receive longer and more
intense treatment regimens.
Recruitment
Recruitment for this study was open from May 2016 through February 2017. A
multi-pronged recruitment approach of convenience sampling with snowballing was
used for this study. Oncology clinics that were part of the Johns Hopkins Medical Center
and Andrews & Patel Associates in the Harrisburg, Pennsylvania area were provided
flyers (Appendix D) and agreed to distribute the flyers for the study. The Young Survival
Coalition (YSC), a national organization based in New York City, advertised the study in
their electronic newsletter and on their Facebook page. Additionally, YSC and Living
Beyond Breast Cancer, a national organization based in Philadelphia, allowed for a
study announcement posting in their closed Facebook Support Groups. In October YSC
posted a guest blog that discussed my journey from breast cancer survivor to
researcher. This blog post contained a link to the study (Appendix D).
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A Facebook page titled ‘The impact of breast cancer treatment on cognition
research study’, @chemoandcognition, was created for this study. This page was linked
to Facebook announcements as well as shared with personal friends and breast cancer
survivors for snowballing. Posts were made on this page with reminders that the study
was still open. Additionally, articles and blogs were shared on the topic of cognition and
breast cancer. The decision was made not to use Facebook paid advertisements as
they could not be targeted precisely enough to reach eligible individuals.
Study announcements were emailed to twenty one face-to-face support groups in
the state of Pennsylvania (Appendix E). One hundred twenty five flyers were distributed
to attendees at the 2016 Young Survival Coalitions Midwest Symposium in Minneapolis,
MN and 200 flyers at the West Coast Regional Symposium in Long Beach, CA.
Additionally, ten flyers were given to individuals at the San Antonio Breast Cancer
Symposium in December 2016 for nurses and advocates to distribute. It was expected
that recruitment would occur over a period of 2-3 months. In total recruitment was open
for 8 months. The plan to recruit through clinics and local support groups combined with
online recruiting was an attempt to reduce coverage error by capturing both social
media users and non-users (Dillman, Smyth & Christian, 2014).
Participants were recruited prior to the completion of chemotherapy or radiation
in order to initiate the first administration of assessments approximately 2-3 weeks post
completion of treatment. The time span of 2-3 weeks provided for flexibility, allowed for
immediate side effects of the chemotherapy or radiotherapy to clear, but still reflected
the baseline cognitive and functional status at the conclusion of treatment. Prior to
enrollment in the study, volunteers were asked to complete an informed consent and
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eligibility questionnaire. These were available through a public link to the VCU
REDCapTM System. The flyer provided an option to call or email for a paper copy of the
consent form and survey. No participants requested this option. Each eligible participant
was asked to recommend a caregiver to participate. Only three participants provided a
caregiver referral. One caregiver referral was the same as a participant and was not
contacted. The other caregivers were contacted via email and did not respond. Table 2
provides an overview of the participant timeline, tasks and time commitment.
Table 2
Participant Timeline
Observation

Required Tasks

Study Entry

Informed Consent

O1 :
Completion
of treatment
(within 3
weeks)
O2 : 3
months post
O1
O3 : 6
months post
O1

Estimated Time
Commitment

Actual Time
Commitment
2-5 minutes

Demographics
PROMIS
assessments
Incentive form.

30-45 minutes

15-35 minutes

Update of
demographics
PROMIS
assessments
Update of
demographics
PROMIS
assessments

30-45 minutes

10-30 minutes

30-45 minutes

10-30 minutes

Sample Size
The original proposal had the goal of recruiting approximately 46 individuals for
each group in this study to achieve a reasonable number of participants anticipated to
complete the six-month study (n=32/group). This corresponds to an approximate 30%
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attrition rate. This rate is similar to the attrition rate reported by Bender et al. (2006) in
their 6-month study of cognition and breast cancer. The sample size was determined
based on feasibility of recruitment and time constraints. If 32 subjects per group
completed the study, then there would be 80% statistical power to detect a difference
between the groups on the order of 0.8 standard deviation units (Cohen’s d = 0.8,
considered a moderate-to-large large effect size). In August 2016, the recruitment goal
was adjusted to achieve a sample size of 16 in each group, which corresponded to a
one SD difference. The final sample size for this study was 16 with seven chemotherapy
subjects and nine chemotherapy + radiation subjects.
Attrition
The risk of attrition was significant as this study followed participants over the
span of six months. Several strategies were employed to reduce the potential loss.
Participants were scheduled for O2 upon completion of O 1 and for O 3 at the completion
of O 2. Participants were sent automatic email from REDCapTM. If a participant did not
respond I sent an additional reminder originating from REDCapTM. Participants were
provided a $10 gift card or donation to YSC incentive upon completion of the first
survey. This amount served as a small thank you token and was not at the amount to be
viewed as coercive (Singer & Couper, 2009). Advance token incentives have been
shown to be effective in improving response rates through establishment of trust and
creation of a social exchange (Dillman et al., 2014). Advance incentives have been
shown to increase response rates more than lotteries and those offered for completion
(Dillman et al., 2014). These incentives were funded through an internal faculty grant
from Elizabethtown College. During the study, participant progress on surveys was
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monitored through REDCapTM. If a participant did not complete any surveys an email
reminder was sent to invite the respondent to return to REDCapTM and complete the
survey.
Data Collection
Study data were collected and managed using REDCapTM electronic data
capture tools hosted at Virginia Commonwealth University (Harris et al. 2009).
REDCapTM. (Research Electronic Data Capture) is a secure, web-based application
designed to support data capture for research studies, providing 1) an intuitive interface
for validated data entry; 2) audit trails for tracking data manipulation and export
procedures; 3) automated export procedures for seamless data downloads to common
statistical packages; and 4) procedures for importing data from external sources. Upon
IRB approval an account was established in REDCapTM.
A welcome page was set up with access to the informed consent and
demographic survey (Appendix A-B). The study was set up into two arms. The first arm
included the welcome, informed consent and eligibility survey. The second arm was for
eligible individuals. As fields were created in REDCapTM they were designated as
private health information as necessary and data permissions were set up to maintain
participant confidentiality. Automatic invitations were set up in the system to invite
participants to complete their first survey three weeks after the treatment finish date
provided in the eligibility survey. REDCapTM generated a unique link for each participant.
The system was set up to send email invitations with a personally unique URL to the
second arm of the study. The second arm contained the demographic surveys and
PROMIS® instruments. The PROMIS® instruments were available in the
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REDCapTM shared library and were uploaded into the study (Obeid et al 2013). The
instruments were programmed to capture Computer Adaptive Testing (CAT) scoring
(Cella, Gershon, Bass & Rothrock, 2014). In CAT the survey questions are adapted by
the computer based on the responses provided on a previous question. CAT decreases
administration time, while maintaining measurement precision (PROMIS, 2015g). The
PROMIS® instruments were set up to avoid redundancy in asking the same item
multiple times in each administration. Prior to launching, the project was tested by
myself and a research assistant/ graduate student from Elizabethtown College.
Statistical Analysis
Data collected through REDCapTM was downloaded into an Excel worksheet.
Data was cleaned and examined for outliers and missing data. The REDCapTM format of
the PROMIS instruments required participants to complete all items, therefore there was
no missing data in this section. Missing data from demographic questionnaires are
indicated in the results section. The data was then uploaded into SAS for analysis.
Descriptive statistics are provided in Chapter 5 for all demographics and scales to
provide a picture of the sample. These include measures of central tendency and
variance.
The original proposed data plan was to use univariate and multivariate repeated
measures analysis of covariance (RM ANCOVA) to compare the changes in cognition
and functional performance variables within groups (HA 1-3). This was changed to linear
mixed effects models for HA 1-2 and a correlation matrix comparing changes in cognition
related variables with changes in functional performance variables for HA 3. For the
between group analysis (H A 4-5), the groups were not matched within the study design;
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therefore, the original analysis plan used propensity scores to account for the inability to
randomly assign participants to treatment groups (Austin, 2011). Due to the small
sample size (N=16) and attrition, linear mixed-effects models were calculated instead.
This approach allowed for both within and between subject analyses and accounted for
the repeated measures. In ANCOVA analysis, missing time point data results in
dropping all the data from analysis. The linear mixed-effects model allowed for the
inclusion of data from eight participants that missed one time point data collection.
Likewise linear mixed-effects modeling was used to examine changes in fatigue,
pain interference, sleep, anxiety and depression both within and between groups. The
small sample size was not adequate to perform the proposed exploratory ANCOVA
analysis to examine the impact of education level, sleep disturbance, pain, depression
and anxiety on T-scores.
This chapter provided an overview of the study design and the changes that were
implemented in the areas of recruitment and data analysis. The following chapter will
provide an in depth presentation of the challenges encountered in recruitment and
enrollment in the study and the actions taken to address the associated issues. The
study results are presented in Chapter 5 and discussed in Chapter 6.
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Chapter Four: Study Recruitment and Enrollment Challenges
“If it doesn’t work, it’s not failure, it’s data.”
-Dorie Clark 2017

In designing research, we typically try to foresee and address threats to validity
and completion of research. These are weighed in relationship to resources available
such as time, money, infrastructure, and researcher capacity. In the design of this study,
efforts were made to balance rigor in research methods with the reality of the disease of
breast cancer treatment profiles and the availability of eligible research subjects. This
chapter provides an overview and discussion of the challenges and obstacles faced in
the enrollment phase. The process of responding to these challenges and the actions
implemented in an attempt to improve enrollment are presented.
Challenges in Recruitment
The proposed design of this study aimed to compare changes in cognition and
everyday functional performance of individuals receiving chemotherapy treatment for
breast cancer to those receiving radiation therapy. The radiation only arm served as the
comparison group to control for the relative effects of the combination of treatments
(Wefel et al., 2011). In order to limit variability and promote homogeneity, regarding type
of chemotherapy, eligible participants must have received an anthracycline/ taxane
based treatment. Additionally, original eligibility required surgery prior to the initiation of
treatment. Initial recruitment was through flyer distribution to patients at Andrews &
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Patel in Central Pennsylvania, Johns Hopkins Medical Center and e-newsletter/ social
media posting by the Young Survival Coalition (YSC). The study announcement
provided options to go online or to obtain paper surveys for participation. A dedicated
phone number was established. The announcements by YSC provided a direct link to
the study informed consent form.
Recruitment initially relied on the cooperation of clinicians, doctors and nurses, to
provide flyers to eligible patients, but this approach did not work effectively. Results
from a focus group study examining the barriers to clinical trial recruitment describe “a
hidden recruitment element’ in which it is necessary to gather support from other
personnel at the clinical site (Stein et al. 2015). Furthermore, Stein et al. report that
investigator/clinicians found it difficult to balance and integrate their own research with
their clinical care. In this study, clinicians were being asked to recruit for a study that
they were not personally invested in. It is possible that issues of this nature impacted
distribution of flyers by medical professionals in this study.
A second recruitment challenge may have been that the clinic flyers placed the
onus on the participant to either go online or call the researcher to enroll in the study. In
retrospect, this approach most likely led to the loss of potential participants. Cancer
treatment is stressful and tiring. Patients may have put the flyer aside instead of taking
the next step. In an effort to encourage flyer distribution, beginning in June 2016
through February 2017, and monthly follow up emails were sent to both clinic contacts
to encourage recruitment. The clinical liaisons replied to all inquiries stating that they
would continue to encourage clinic staff to distribute flyers. This points to another issue
within the study, the lack of tracking for flyer distribution. The clinical sites offered to
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make their own copies to distribute. If numbered flyers were sent to the site, the site
liaison would have been able to easily report the number of flyers distributed.
The ability to recruit participants for this study within a reasonable time frame
was overestimated. This common tendency of researchers, especially novice or junior
researchers, is referred to as a ‘funnel effect’ or Lasagna’s Law (Gul & Ali, 2010; Stein
et al. 2012). Low enrollment and nonresponse rates can prolong the time of studies, can
lead to invalid or inconclusive results secondary to diminished statistical power, results
in poorly used human and material resources and threatens the internal and external
validity of research studies (Carlisle et al. 2015; Gul & Ali, 2010; Williams, Tse, DiPiazza
& Zarin, 2015).
Insufficient accrual of participants for clinical trials is often a top reason for
termination. In 2013, a review of the ClinicalTrials.gov database found 57% of 619 trials
terminated for nonscientific reasons resulted from insufficient rate of accrual (Williams et
al. 2015). A study utilizing the National Library of Medicine clinical trial registry identified
481 (19%) out of 2579 studies terminated for less than 85% of expected enrollment
(Carlisle et al. 2015). Finally, volunteers participate in research studies to contribute to
meaningful scientific knowledge. When studies are not sufficiently enrolled an ethical
issue arises in regards to the volunteers and may deplete the available pool of
participants (Carlisle et al, 2015; Williams et al. 2015).
Efforts to Expand Enrollment
Within two months of opening enrollment to the study, it became apparent that
many interested participants were not qualifying for the study. In July a page for the
study was created on Facebook (https://www.facebook.com/ chemoandcognition/) and
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an amendment to the study IRB was submitted and approved. The study link was
shared on two closed Facebook support groups. This resulted in over twenty new logins
to the survey. The initial analysis of participant characteristics showed that interested
participants were ineligible due to receiving both chemotherapy and radiation, or
because they were receiving neoadjuvant treatment. The dissertation committee was
reconvened in August 2016 and the study design was altered to include a
chemotherapy and radiation treatment group, as well as including individuals receiving
neoadjuvant treatment. The protocol changes were approved by the VCU IRB.
Individuals who completed the consent process and were then eligible to participate
were emailed and invited to return to the study.
In addition to the changes in protocol, recruitment efforts were expanded.
Twenty-one in person support groups in the state of Pennsylvania were contacted via
email between June and September 2016 (Appendix E). Three groups responded and
agreed to distribute the study flyer. Study announcements were posted in eight closed
Facebook support groups with permission from the group administrator. Closed groups
on Facebook require approval to join and individuals must demonstrate that they have
been diagnosed with breast cancer. Monthly re-posts of the study announcement were
made between August 2016 and January 2017.
Posting on Facebook was intentionally made within closed support groups. This
did not prevent the link from being shared. In Mid-July 2016 over a span of three days,
56 records were created on REDCapTM. Evidently the link was shared and there were
attempts to gain access to receive the incentive gift card. The eligibility screening
questionnaire worked well in this case. Responses for date of diagnosis and end of
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treatment dates needed to match up in order to qualify. This type of misrepresentation is
associated with the lack of face-to-face contact in the recruitment process and is a clear
risk associated with the use of Facebook for recruitment (Pedersen & Kurz, 2016). The
low yield and completion rate observed in this study is consistent with other studies
utilizing Facebook for recruitment (Kapp, Peters & Oliver, 2013; Ramo & Prochaska,
2012).
One hundred and twenty five flyers were distributed at the Young Survival
Midwest Symposium in June 2016 and 200 copies at the West Coast Symposium in
October 2016. In October, 2016 a guest blog was posted on the YSC website about my
journey from breast cancer survivor to doctoral student researcher which included a link
to the study (Appendix D).
In November, 2016 an electronic flyer was emailed and 20 paper copies were
mailed to committee member Dr. Albrecht for distribution through her clinic work setting.
Additionally, three local nursing oncology groups were emailed with a request to
distribute flyers and to make a presentation at their local meetings. One group replied
stating they would distribute the flyer to their members. A presentation to the Oncology
research group at Penn State Hershey Medical center was given in November 2016 and
both medical oncologists and radiation oncologists agreed to distribute flyers. An
electronic copy of the flyer was sent to research group coordinator and twenty paper
flyers were passed out at the meeting. In December 2017, an electronic copy and 5
paper flyers were provided to an oncology nurse in San Francisco and to the Cancer
Resource Center in Ithaca, NY.
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Eligibility Challenges
The initial study design required that participants had surgery prior to initiating
chemotherapy or radiotherapy. This design did not recognize a shift in breast cancer
treatment toward the use of neoadjuvant chemotherapy and/ or radiotherapy, treatment
provided before surgery, and negatively impacted enrollment. Of the first 50 individuals
to start the enrollment process in the study three did not qualify because they were
receiving neoadjuvant treatment. Additionally, comments to the Facebook
announcements indicated interest among individuals who were ineligible because they
had not had surgery prior to chemotherapy.
The study design was based on the traditional approach in which breast cancer
is treated with surgery and adjuvant treatment of chemotherapy, and/or radiation
therapy, and/or endocrine therapy. The recent shift to neoadjuvant chemotherapy allows
oncologists to determine if an individual has a pathologic complete response (pCR),
meaning that there is no tumor left after the treatment. A pCR is associated with a
survival benefit (Teshome & Hunt, 2014). With newer molecular technology,
neoadjuvant treatment models identify both exceptional responders and non-responders
(Chatterjee & Erban 2017). This approach also improves rates of less-invasive breast
conservation surgery, quicker recovery and post-operative complications such as
lymphedema (Chatterjee & Erban 2017; Steenbrugen et al. 2017; Teshome & Hunt,
2014). Shifts in standards of care, such as experienced with this study, are known to
impact clinical accrual (Carlisle, Kimmelman, Ramsay & MacKinnon, 2015). The
inclusion of individuals with surgery before or after chemotherapy treatment introduces
additional confounding variability. The study protocol was changed in August 2016, with
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committee approval, to include individuals receiving neoadjuvant treatment. With this
change five participants entered and completed the study.
Technology Issues
At least ten times during data collection there was a glitch in REDCapTM and the
survey queue failed to load automatically for participants. One participant emailed
regarding the problem. Additionally, the problem was observed through monitoring of
REDCapTM confirmation emails. The VCU REDCapTM administrators were contacted
regarding this issue and they confirmed it was a problem within the entire
REDCapTM system. When this occurred, an invitation to return and complete the survey
was sent to the participant via REDCapTM. This strategy helped to reduce missing data
in these instances.
Summary
Throughout the recruitment phase of the study the researcher was responsive to
recruitment challenges and attempted to develop new sources for participants. Prior to
implementation, strategies were discussed with the dissertation advisor and/or
committee. When necessary, IRB amendments were submitted for approval. Despite
these best efforts, the desired sample size was not met. This study included the
following barriers to enrollment: a significant number of eligibility criteria, reliance on
clinic staff to provide flyers to eligible patients, and reliance on volunteers to go online to
enroll in the study. Positive recruitment efforts included modifying eligibility, adding
recruitment sites and support group outreach.
The following chapter provides a summary of the progression of participants
through the study and the results of the study. Demographics, descriptive data and
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hypothesis analysis are provided. Chapter 6 provides a discussion of the results in the
context of current published literature, study limitations and implications of this study for
occupational therapy and oncology professions.
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Chapter Five: Results

The purpose of this study was to better understand the impact of PBCCI on
activities and participation during the six months following the conclusion of
chemotherapy and/or radiotherapy for breast cancer. In this study participants receiving
either chemotherapy or chemotherapy + radiotherapy completed online self-report
surveys regarding their physical function, social function, cognition and related
confounding factors including sleep interference, pain, depression, fatigue and anxiety,
at the conclusion of treatment, and at three and six months later. This descriptive study
utilized a longitudinal post-test only design with nonequivalent groups (Shadish, Cook &
Campbell, 2002). In this chapter, the study results are presented, beginning with an
overview of the participants followed by descriptive data framed by Hess & Insel’s
(2007) Conceptual Model of Chemotherapy-Related Changes in Cognitive Function
concluding with the hypothesis related analysis.
Participants
Participants were recruited through clinics, snowballing, support groups, and
Facebook. Sixteen women, ages (28-45) participated in this study. The majority of these
participants (n=12, 75%) are considered younger women (age<40 years) in the
oncology field (Gabriel & Domchek, 2010). Nine received chemotherapy + radiotherapy
and seven received chemotherapy. Nine women that received radiotherapy only
completed the consent process, but were ineligible due to being more than 3 weeks out
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of treatment. Recruitment for this study was challenging and an in-depth review of
recruitment procedures and challenges is provided in Chapter 4. Figure 3 provides an
overview of the progression of participants in the study and reasons for ineligibility.
There was an overall 50 percent attrition rate over the six month follow up. The
chemotherapy group had an initial enrollment of n=7, decreasing to n=3 at the three
month follow up and n=2 at the six month follow up. In the chemotherapy + radiotherapy
the initial enrollment was n=9, decreasing to n=7 at three months and n=6 at six
months.
Cancer Related Demographics
Table 3 provides an overview of breast cancer related demographics. The table
covers diagnosis, treatment and physiologic factors that are known to be involved in
cognitive changes associated with cancer treatment (Hess & Insel, 2007; Myers 2009).
Two participants in the chemotherapy group had zero positive lymph nodes and five did
not report a number of positive nodes. In the chemotherapy + radiotherapy group, one
participant reported zero positive nodes. The other participants in this group ranged
from 1-7 positive nodes. This is expected as radiotherapy is more prevalent when there
is lymphatic involvement.
Situational Factors
In the Conceptual Model Of Chemotherapy-Related Changes in Cognitive
Function, Hess and Insel (2007) define the situational factors of lifestyle and personal
experience. Lifestyle includes employment, and personal experience includes marital
status and social support. Fifteen women identified themselves as white and one as
other. All the women in the chemotherapy + radiotherapy group were married (n=9), one
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Entered REDCap TM
N=149

Blank Consent
n=43

Initiated Informed Consent
N=106

Completed Informed
Consent
N=92

Incomplete Contact Info
n=14

Diagnosed previously with another type of
cancer
n=3

Stage IV
Breast Cancer
n=1
Stage I-IIIa
Breast Cancer N=89

Included in Analysis
O1
N=16
Chemotherapy n=7
Chemotherapy + Radiotherapy
n=9

O2
N=12
Chemotherapy n=5
Chemotherapy + Radiotherapy
n=7

Duplicate entries
n=20

Epilepsy n=1
Learning Disability n=1
History of Substance Abuse n=1
Hospitalization for Mental Illness n=1

Finished Treatment > 3 weeks
prior to enrollment
n=43
Chemotherapy +
Radiotherapy
prior to eligibility change
n=5

O3
N=8
Chemotherapy n=2
Chemotherapy + Radiotherapy
n=6

Figure 3: Participant enrollment and retention.
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Radiotherapy
n=9

Table 3
Demographics: Antecedents and Physiologic Mediators According to the Revised
Conceptual Model of Chemotherapy-Related Changes.
Chemotherapy
(n=7)
Stage of Cancer at Diagnosis

Total
(N=16)

I: 2
II: 5
III: 0

Chemotherapy +
Radiotherapy
(n=9)
I:2
II: 4
III: 3

0
4
0

3
3
4

3
7
4

1
2
2
0
2

2
1
2
1
3

3
4
4
1
5

0
4
2
4
0
4

8
1
5
1
0
6

8
5
7
5
0
10

6
1

9
0

15
1

3
1
0
3

0
0
2
7

3
1
2
10

0
2
1
0
0
3
4
1

1
0
1
2
1
2
3
2

1
2
2
2
1
5
7
3

I: 4
II: 9
III: 3

Surgery Type
Lumpectomy
Simple Mastectomy
Modified Radical Mastectomy
Type of Chemotherapy
Standard AC-T
Dose-Dense AC-T
TAC
TC
Other
Tumor Characteristics
ER+
ERPR+
PRHER2+
HER2Menopausal status at diagnosis
Pre-menopause
Peri-menopause
Menopausal status at start of
study
Pre-menopause
Peri-menopause
Post-menopause
Chemo-induced menopause
Type of Hormonal Therapy
Tamoxifen
Zoladex
Lupron
Arimidex
Aromasin
Lymphedema Diagnosis
Low Levels of Vitamin D
Anemic at start of study
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woman in the chemotherapy group (n=7) reported living with a partner, the others were
married. None of the participants reported that they smoke or vape. Table 4 provides an
overview of the education status and Table 5 shows employment status. A total of 7
participants (chemotherapy n=2, chemotherapy + radiotherapy n=5) reported their
employment status changed after their diagnosis with breast cancer. Four participants in
the chemotherapy group were parents compared with six in the chemotherapy +
radiotherapy group. One participant in the chemotherapy group reported caregiving for
an adult.
Table 4
Education Level.

Chemotherapy
Chemotherapy
+
Radiotherapy
Total

Doctoral or
Professional
Degree
0
1

Master
Degree
2
1

Bachelor
Degree
2
4

Associate
Degree
0
1

PostSecondary
Nondegree
Award
1
1

1

3

6

1

2

Some
College
No
Degree
2
1

Total
7
9

3

16

Table 5
Employment Status.
Chemotherapy
Chemotherapy
+
Radiotherapy
Total

Full-time
4
6

Part-time
2
1

Volunteer
0
1

Homemaker
1
1

Total
7
9

10

3

1

2

16

Psychosocial Factors
Stress, depression, anxiety and distress are psychosocial factors associated with
cognitive changes in the Conceptual Model Of Chemotherapy-Related Changes in
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Cognitive Function (Hess & Insel, 2007). Depression and anxiety may also be a
concurrent symptom related to cancer treatment that impacts health-related quality of
life. Participants were asked if they had a history of anxiety and if they had a history of
depression. Six participants reported a history of anxiety, one in the chemotherapy
group and four in the chemotherapy + radiotherapy group. Four individuals reported a
history of depression, all in the chemotherapy + radiotherapy group. Two participants in
the chemotherapy group did not answer this question.
PROMIS® Descriptive Data
Each participant completed the PROMIS® instruments measuring cognition,
physical function, social participation, anxiety, depression, fatigue, pain interference,
and sleep interference at the three time points. Table 6 provides a summary for each
domain for the chemotherapy group and the chemotherapy + radiotherapy group at
each observation point. Using Computer Adaptive Testing (CAT) in REDCapTM,
participant scores were automatically converted from raw scores to a standardized Tscore. For all PROMIS® measures, the T-score has a mean of 50 and a standard
deviation of 10. The PROMIS-57 Profile v2.0 contains scales to measure depression,
anxiety, fatigue, sleep interference and pain interference (PROMIS 2015f). These
scales were normed on the general population of the United States. Higher scores
represent more of the concept being measured and lower scores represent less.
Fatigue and anxiety were one standard deviation higher than the norm for the general
population of the US for the chemotherapy + radiation group, across all three time
points. Depression scores were one standard deviation higher than the norm for the
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Table 6
Summary of T-Score Means on PROMIS Domains.
Observation 1
(Baseline)
Chemo Chemo+Rad
n=7
n=9

PROMIS Domain
Physical Function

Observation 2
(3 Months)
Chemo
Chemo+Rad
n=4
n=7

Observation 3
(6 Months)
Chemo Chemo+Rad
n=2
n=6

Mean

44.96

42.59

48.20

43.17

52.80

42.93

Median

43.9

42.90

45.20

41.40

54.10

43.50

CognitionConcerns

Mean

36.59*

41.22

37.18*

42.56

38.45*

45.72

Median

42.60

39.60

37.25

41.20

38.45

42.25

Cognition- Abilities

Mean

49.10

44.24

50.98

43.27

46.40

38.83*

Median

48.50

43.60

51.75

43.50

46.40

41.45

Mean

46.21

47.68

51.35

44.40

54.60

46.77

Median

43.80

47.80

48.85

44.70

54.60

51.20

Satisfaction with
participation

Mean

50.91

45.77

50.23

43.30

48.15

44.58

Median

48.00

45.80

51.55

44.30

48.15

49.05

Depression

Mean

59.07

57.64

55.25

60.70**

57.75

61.85**

Median

59.80

57.60

58.40

62.25

57.75

59.60

Mean

58.16

61.10**

57.50

66.05**

61.20**

67.17**

Median

60.00

63.40

60.25

67.45

61.20

67.80

Mean

56.66

62.28**

52.80

61.30**

55.50

61.58**

Median

57.50

61.20

53.40

60.90

55.50

61.95

Mean

59.07

55.89

49.65

60.70**

50.85

58.18

Median

62.80

56.40

49.35

61.60

50.85

54.05

Mean

52.43

56.41

49.65

55.22

48.60

59.47

Median

51.10

56.30

49.35

53.45

48.60

59.10

Ability to Participate

Anxiety

Fatigue

Pain Interference

Sleep Interference

Note. PROMIS® T-Scores have a mean of 50 and a standard deviation of 10. * One standard deviation
below the PROMIS® instrument population norm. **One standard deviation above the PROMIS®
instrument population norm.

three and six month time points. This means the participants in this sample report
higher levels of fatigue, anxiety and depression than would be expected.
The PROMIS Physical Function Ca Bank v1.1 was calibrated with individuals
diagnosed with different types of cancer (PROMIS 2015a). The PROMIS Ability to
Participate in Social Roles v2.0 and PROMIS Satisfaction with Social Roles and
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Activities v2.0 scales were calibrated with individuals with chronic illness that were
sicker than the general population (PROMIS 2015e). The PROMIS Applied Cognitive
Abilities v1.0 and the PROMIS Applied Cognitive General Concerns v1.0 were
calibrated on samples enriched for chronic illness (PROMIS, 2015d). In this study, the
chemotherapy only group was more than one standard deviation below the norm on the
cognitive concerns scales across the six month span of the study (see Table 6). This
may be interpreted as the group having fewer concerns than the normed population
which was enriched for individuals with chronic illnesses. Cognitive ability t-scores for
the chemotherapy + radiotherapy group did not change significantly during the study but
fell to one standard deviation below the norm at the six month follow up. This result
shows lower cognitive abilities than expected for a chronically enriched population
Hypothesis Tests
HA 1: Cognition, as measured by the PROMIS Applied Cognition abilities and
concerns scales, will improve within each group across the three measurement time
points.
There was no significant change in cognition for either group over the six months
post treatment as measured on either the abilities scale or the concerns scale (See
Table 7). Cognitive concerns were one standard deviation lower than the PROMIS norm
across all three time points for the chemotherapy only group, meaning this sample
reported lower level of concerns with cognition. At the six month follow up the
chemotherapy + radiotherapy group was one standard deviation below the norm for
cognitive abilities. This may be interpreted as the group having lower cognitive abilities
than expected.
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Table 7
Linear Mixed Effects Model Summarizing Changes in Cognition as Measured by the
PROMIS Applied Cognition Scales According to Treatment Group Over The Six Months
Following the Completion of Treatment.

Chemotherapy Slope
Cognition- Concerns
Cognition- Abilities
Chemotherapy+Radiotherapy Slope
Cognition- Concerns
Cognition- Abilities

Estimate

Standard
Error

df

tValue

PR>ItI

1.6971
-0.4419

1.3756
1.5505

14
14

1.23
-0.29

0.2376
0.7798

-0.4751
-0.9322

0.6919
0.9953

14
14

-0.69
-0.94

0.5035
0.3649

Note. Slope estimates were calculated using mean changes in PROMIS ® T-scores at the three time
points- three weeks post treatment, three months post treatment and six months post treatment.

HA 2: Functional performance as measured by the PROMIS Cancer Physical
Function Scale, the PROMIS Ability to Participate Scale, and the PROMIS Satisfaction
with Social Roles and Activities will improve within each group across the three
measurement time points.
Physical function as measured on the PROMIS scale improved significantly in
the six months post treatment in the chemotherapy only group, but not in the
chemotherapy + radiotherapy group. Ability to participate, as measured on the PROMIS
scale, improved significantly for the chemotherapy + radiation group, but not for the
chemotherapy only group. There was no significant change for either group in
satisfaction with social roles and activities (see Table 8).
HA 3 : Change in cognition will positively correlate with change in functional
performance within each group
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Table 8
Linear Mixed Effect Model Summarizing Changes in Functional Performance by
Treatment Group Over the Six Months Following the Completion of Treatment.
Estimate Standard
Error
Chemotherapy Slope
Physical Function
3.3142
Ability to Participate
3.3969
Satisfaction with Social
-0.6809
Roles
Chemotherapy + Radiotherapy Slope
Physical Function
1.8450
Ability to Participate
2.8475
Satisfaction with Social
1.8454
Roles

df

tValue

PR>ItI

1.2340
2.4752
2.6353

14
14
14

2.69
1.37
-0.26

0.0178*
0.1915
0.7999

0.9147
1.2976
1.6475

14
14
14

2.02
2.20
1.12

0.0633
0.0447*
0.2815

Note. Slope estimates were calculated using mean changes in PROMIS ® T-scores at the three time
points- three weeks post treatment, three months post treatment and six months post treatment.
*significant at p<0.05

A Pearson’s correlation matrix was used to examine the correlation of changes in
cognitive variables with changes in the functional performance variables for eachgroup
over time. A 95% confidence interval (CI) was calculated to determine significance of
the correlations. The correlations provide only descriptive data about the direction of
relationships. All correlations fell within the 95% CI for the chemotherapy + radiotherapy
group, this was not the case for the chemotherapy only group. Appendix F contains the
95% CI tables for all variables in both groups.
Table 9 provides a summary of all correlations for the chemotherapy group.
Of the three constructs used to define functional activity, physical activity, ability to
participate and satisfaction with participation, only physical activity showed a significant
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Table 9
Chemotherapy: Correlations among Mean PROMIS® T-score Changes over Six Months
Post Treatment.

Variable
Physical
Function
Cognitive
Concerns
Cognitive
Abilities

Physical
Function

Cognitive
Concerns

Cognitive
Abilities

Depression

Anxiety

Fatigue

Pain
Interference

Sleep
Interference

Ability to
Participate
in Social
Roles

-0.6661*
0.6252

-0.6075

Depression

-0.5265

0.5471

-0.7156*

Anxiety

-0.7559*

0.8321*

-0.6556*

0.5068

Fatigue
Pain
Interference
Sleep
Interference
Ability to
Participate
in Social
Roles
Satisfaction
w ith Social
Roles

-0.7306*

0.6864*

-0.7484*

0.5675

0.6574*

-0.6693*

0.3967

-0.4655

0.4364

0.4986

0.6283

0.5154

-0.4826

0.5019

-0.5203

-0.5584

-0.5584

-0.5765

0.7338*

-0.5461

0.6192

-0.5592

-0.4834

-0.6222

-0.4823

0.3759

-0.4048

0.4504

-0.5841

0.4088

0.4745

0.5306

0.4449

-0.3473

-0.4956

Note. Appendix F contains a full listing of the 95% Confidence Intervals.
*significant at p<.05

negative correlation (p<.05) with cognitive concerns, r=.-.66, 95% CI [-.91, -.05].
Likewise, a similar relationship of a significant negative correlation was observed for
these two constructs in the chemotherapy + radiotherapy group (see Table 10). The
chemotherapy + radiotherapy group showed a significant (p<.05) negative correlation
for cognitive concerns and the ability to participate in social roles r=-.59, 95% CI [-.79, .27]. Within the chemotherapy + radiotherapy group, cognitive abilities were
significantly, positively correlated with these two variables. This means as cognitive
concerns decreased or lessened over time and cognitive abilities improved over time,
physical function and ability to participate in social roles improved. An inverse
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Table 10
Chemotherapy + Radiotherapy: Correlations among Mean PROMIS® T-score Changes
over Six Months Post Treatment.

Physical
Function

Variable

Cognitive
Concerns

Cognitive
Abilities

Depression

Anxiety

Fatigue

Pain
Interference

Sleep
Interference

Ability to
Participate
in Social
Roles

Physical
Function
Cognitive
Concerns

-0.6917*

Cognitive
Abilities

0.6551*

-0.6367*

Depression

-0.5659*

0.5821*

-0.7377*

Anxiety

-0.7781*

0.8455*

-0.6864*

0.5536*

Fatigue
Pain
Interference
Sleep
Interference
Ability to
Participate
in Social
Roles
Satisfaction
w ith Social
Roles

-0.7542*

0.7118*

-0.7698*

0.6061*

0.6917*

-0.6994*

0.4483*

-0.5132*

0.4895*

0.5507*

0.6651*

0.5722*

-0.5387*

0.5592*

-0.5799*

-0.6456*

-0.6155*

-0.6331*

0.7478*

-0.5877*

0.6396*

-0.5834*

-0.5158*

-0.6437*

-0.5148*

0.4261*

-0.4366*

0.4781*

-0.6047*

0.4404*

0.5041*

0.5555*

0.4765*

-0.3945*

-0.5164*

Note. Appendix F contains a full listing of the 95% Confidence Intervals.
*significant at p<.05

relationship occurred in respect to the correlation of cognition and the satisfaction with
participation in social roles. As cognitive concerns lessened over time and cognitive
abilities improved, satisfaction with participation in social roles increased. No causation
or significance may be determined from correlational analysis.
HA 4: Cognition, as measured by the PROMIS Applied Cognition abilities and
concerns scales will differ between the chemotherapy and chemotherapy + radiotherapy
groups.
The linear mixed-effects model was used to compare the slopes of the cognition
variables for the chemotherapy group with the chemotherapy + radiotherapy group. No
significant differences were observed between the two groups over time for cognitive
73

concerns (Estimate: 2.1723, SE: 1.5397, DF: 14, t: 1.141, PR>ItI 0.1801) and cognitive
abilities concerns (Estimate: 0.4903, SE: 1.8425, DF: 14, t: 0.27, PR>ItI 0.7941).
HA 5: Functional performance as measured by the PROMIS Cancer Physical
Function Scale, the PROMIS Ability to Participate Scale, and the PROMIS Satisfaction
with Social Roles and Activities will differ between the chemotherapy and
chemotherapy + radiotherapy groups.
No significant differences between the two groups were observed on the
functional performance variables when analyzed in the linear mixed-effects model as
seen in Table 11.
Table 11
Comparison of Chemotherapy and Chemotherapy + Radiotherapy Groups on
Functional Performance
Estimate
Physical Function
Ability to Participate
Satisfaction with Social
Roles

1.4692
0.5494
-2.5263

Standard
Error
1.5361
2.7919
3.1079

df
14
14
14

tValue
0.96
0.20
-0.81

PR>ItI
0.3551
0.8468
0.4299

Exploratory Analysis of Psychosocial Factors and Concurrent Symptoms
Depression and anxiety are viewed as both psychosocial factors and concurrent
symptoms in the Revised Conceptual Model of Chemotherapy-Related Changes in
Cognitive Function (Myers, 2009). Fatigue and pain interference are considered
concurrent symptoms. Sleep interference is not specifically mentioned in this guiding
model, but is included as a construct in the PROMIS-57 and was included in this study’s
analysis. Table 12 provides a summary from the linear mixed-effects model examining
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Table 12
Slope Estimates for Psychosocial Factors and Concurrent Symptoms Within and
Between Treatment Groups.
Estimate Standard
Error
Chemotherapy Slope
Depression
-2.7139
Anxiety
1.2185
Fatigue
-0.2326
Pain Interference
-3.5960
Sleep Interference
-0.6226
Chemotherapy + Radiotherapy Slope
Depression
-2.1571
Anxiety
0.8805
Fatigue
-3.3835
Pain Interference
0.7311
Sleep Interference
1.2085
Chemotherapy Vs Chemotherapy + Radiotherapy
Depression
-0.5567
Anxiety
0.3381
Fatigue
3.1509
Pain Interference
-4.3271
Sleep Interference
-1.8311

DF

tValue

PR>ItI

2.2720
1.5136
2.1281
2.1679
1.5570

14
14
14
14
14

-1.19
0.81
-0.11
-1.66
-0.40

0.2521
0.4343
0.9145
0.1194
0.6953

1.3080
0.8326
1.2210
1.3360
0.9488

14
14
14
14
14

-1.65
1.06
-2.77
.055
1.27

0.1214
0.3082
0.0150*
0.5929
0.2235

2.6216
1.7275
2.4535
2.5465
1.8233

14
14
14
14
14

-0.21
0.20
1.28
-1.70
-1.00

0.8349
0.8477
0.2199
0.1114
0.3323

Note. Slope estimates were calculated using mean changes in PROMIS-57 T-scores at the three time
points- three weeks post treatment, three months post treatment and six months post treatment.
*significant at p<.05

depression, anxiety, fatigue, pain interference and sleep interference. There were no
significant differences between groups on these five constructs.
Fatigue was significant (Table 12) in the chemotherapy + radiotherapy group with
fatigue decreasing in the six months following treatment. Mean t-scores for fatigue were
above 60 for all time points in this group (Table 10). This is one standard deviation
greater than the general population of the United States. Although there were not
significant changes over time for anxiety and depression in this group, their T-scores
were also one standard deviation below the norm (Table 10).
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Summary
In summary, the sample (N=16) in this study is considered young (ages 28-45) in
regards to breast cancer research. Depression, anxiety and fatigue were at least one
standard deviation higher than the normal US population in the chemotherapy +
radiotherapy group. A significant improvement in physical function was found in the
chemotherapy only group in the 6 months post treatment. Ability to participate in social
roles and activities significantly improved in the chemotherapy + radiation group.
Fatigue was a significant symptom for the chemotherapy + radiation group. There were
no significant differences between the groups on any of the constructs measured in the
study. There were no significant changes in self-reported cognition over the course of
the study in either group. The following chapter will discuss these results and the study
limitations within the context of current evidence and provide recommendations for
future research and occupational therapy practice.
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Chapter 6: Discussion

The goal of this study was to better understand how cognition and functional
performance change after breast cancer treatment in order to better inform occupational
therapists and oncology professionals about the challenges breast cancer survivors
face after treatment in returning to their life’s roles and responsibilities. The original
proposal for this study intended to compare individuals who underwent chemotherapy
for breast cancer to individuals who received only radiotherapy for their breast cancer at
3 evenly spaced time periods in the six months after completion of treatment. It became
apparent several months into the study enrollment that it was going to be challenging to
enroll the radiotherapy only group. The study enrollment criteria were expanded to
include a group of individuals that received both chemotherapy and radiotherapy which
served the purpose of maintaining a comparison group. The sample size (N=16), with
seven participants in the chemotherapy group and nine participants in the
chemotherapy + radiotherapy group, limits the ability to generalize results and draw
conclusions from this study.
Much can be learned from both the process of research and study design
employed in this study. In this chapter an overview of the findings placed in the context
of study aims and existing literature will be presented. Next, the limitations of the study
will be discussed followed by a summary of implications for occupational therapy
research and practice, and suggestions for further research.
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Cognitive Performance Findings
The primary aims of this study were to measure changes in cognition and
functional performance over the 6 months following the completion of treatment for
breast cancer and to compare the changes between the two groups. Survivors of breast
cancer report problems with cognition for many years after treatment. It is not clear how
the reported changes in cognition impact the ability to participate in everyday activities.
In this study, cognition was measured in terms of concerns or negative effects, and
abilities or positive effects. There were no significant differences between the
chemotherapy only group and the chemotherapy + radiotherapy group in regards to
either measure of cognitive functioning. Neither group showed significant changes in
cognition over the 6 months after the conclusion of treatment. This is in contrast to the
study hypothesis predicting an improvement in cognition over time. It was surprising that
the chemotherapy group was one standard deviation below norms on the PROMIS
Applied Cognition Cognitive Concerns scale across all three time points. In the
chemotherapy + radiotherapy group, there was a decline in cognitive abilities that
dipped to one standard deviation below normal at the six month follow up. If
chemotherapy is the primary contributor to cognitive impairments then one would expect
for cognition to improve as the drugs clear the system. Consideration must be made for
other physiologic, psychosocial and situational factors that are simultaneously impacting
cognition and functional ability.
Within the published literature, self-reported cognitive declines are common for
women who have been diagnosed with breast cancer and undergone treatment (Collins
et al., 2013; Ganz et al., 2013; Jenkins et al., 2006; Quesnel et al., 2009). Anecdotal
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self-reports of cognitive problems occurred during recruitment for this study in response
to the Facebook recruitment postings in closed support groups. Survivors that were too
far out of treatment to participate provided encouragement and shared their challenges
in their comments:
“Cool, We’re not dead yet”
“I’m struggling with short term memory loss”
“I have been out of treatment since 2007 but was wondering how you managed
to go back to school? I was on 26 at dc, now 35 and I want to but am terrified bc I
still have cognitive issues”
“If u ever do 5yrs out id love to help. Because im affected everyday”
Functional Performance Findings
Within current published literature there is a gap in the understanding of
resumption of functional performance for cancer survivors. Functional performance as
narrowly defined in terms of physical impairments and the ability to perform basic
activities of daily living, as measured in previous studies, stops short of considering the
full spectrum of activities humans participate in (Brearly et al., 2011; Jansen et al., 2011;
O’Toole et al., 2015). Several qualitative studies have explored areas of instrumental
activities of daily living and employment (Braithwaite et al., 2010; Ogilvy, Livingstone &
Prue, 2008; Player et al., 2014). This is the first study to quantitatively look at cognitive
performance and functional performance in broad terms including physical abilities,
social participation and personal satisfaction with social participation.
Functional performance was represented by the constructs of physical function,
ability to participate in social roles and activities, and satisfaction with social roles and
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activities in this research. In the six months following treatment the chemotherapy only
group showed significant gains in physical function. For both groups the mean T-scores
were lower than 50 which is below the average for a general cancer population (but
within 1SD). The chemotherapy group reported higher levels of physical functioning
than the chemotherapy + radiotherapy group, however this was not a significant
difference. In a 6 month longitudinal study of breast cancer survivors, Jansen et al.
(2011) reported greater deficits in motor function associated with taxane based
treatment (Jansen et al. 2011). All participants in this study received a taxane based
chemotherapy treatment.
The chemotherapy + radiotherapy group showed significant positive changes in
their ability to participate in social roles and activities over the six month time period
after treatment. There was not a significant change in the reported satisfaction with
participation in social roles and activities in either group. Occupational therapists are
concerned with both the ability to participate in meaningful activities and an individual’s
satisfaction. The levels of anxiety, depression and fatigue were one standard deviation
higher than the norms for the general US population. These concurrent psychosocial
factors may potentially be impacting satisfaction.
Psychosocial Factors and Concurrent Symptoms
An additional aim of this study was comparison of changes in cognition and
functional performance with the mediating factors of anxiety, depression, fatigue, sleep
disturbance and pain interference. Participants in this study provided self-reports about
their feelings of depression, anxiety, fatigue, and how well they sleep, in addition to how
pain interferes in their ability to participate in everyday activities. The chemotherapy +
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radiotherapy group’s mean anxiety scores were one standard deviation higher than the
average US population for the entire six month time follow up period. Anxiety has been
associated with self-reported cognitive problems for individuals treated for breast cancer
(Biglia et al., 2011; Jansen et al., 2011). In designing this study, evidence relating to
fear of reoccurrence, which is most likely tied into levels of anxiety, in breast cancer
survivors was not examined. With the high levels of anxiety reported by participants and
evidence showing a correlation of anxiety with decreases in self-reported cognition,
exploration of the impact of fear of reoccurrence on participation in occupations is
warranted. In the clinical setting, occupational therapists can provide interventions to
assist clients with coping and compensating for their anxiety.
Mean t-scores for reports of depression did not change significantly during the
study for either group and were above the standardized score of 50. Depression has
been associated with an increase in self-report cognitive problems in several studies
(Bender et al., 2009; Biglia et al., 2011; Jansen et al., 2011). Higher levels of depression
were also associated with higher levels of fatigue (Jansen et al., 2011). Positive
correlations between depression and fatigue were present for both groups in this study
(Refer to Tables 9 & 10).
Fatigue scores dropped significantly in the chemotherapy + radiotherapy group
during the six month period after treatment. The mean fatigue T-score for this group
immediately after treatment was 62.28 dropping to 61.58 at six months, over 1SD
greater than average over the entire study period. Fatigue scores were lower in the
chemotherapy only group than the chemotherapy + radiotherapy group and did not
significantly change over the six month follow up. The higher rates of fatigue in the
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chemotherapy + radiotherapy group may be the result of the cumulative effects on the
body from the treatments. In a recent study by Kishan et al. (2016) breast cancer
patients reported increasing fatigue over the course of treatment, interestingly one of
the predictors for higher level fatigue was younger age (>45). The majority of
participants in this study were also younger. Fatigue is commonly associated with
tiredness. The quality of sleep also impacts tiredness. In this study participants reported
sleep disturbance levels above average, and the chemotherapy + radiotherapy group
reported an increase in sleep disturbance further out from treatment. Anxiety,
depression, fatigue, pain and sleep disturbance appear to be interrelated and it is
extremely difficult to tease out the influence of each on cognition and functional
performance. The small sample size limited the ability to perform post hoc analysis to
explore trends in the relationship of these mediating factors to changes in cognition and
functional performance.
Limitations
This was a small study with limited generalizability. The recruitment goal was for
92 participants (46 per group) with the expectation of a 30% attrition rate. Recruitment
for this study took place over a period of 10 months and only 16 participants met
eligibility requirements and participated. Over the six month time period for follow up the
attrition rate was approximately 50%. Follow ups during this study consisted of email
communications.
The small sample size and high attrition rate resulted in a need to alter the data
analysis plan. The planned analysis with RM ANOVA and RM ANCOVA were replaced
with linear mixed-effects models. Linear mixed-effects modeling allow for analyzing
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repeated measures at the independent level, can be used when independence is
violated and can use all data points, even if the individual did not complete the time
series (Tabachnik & Fidell, 2007). The small sample size eliminated the ability to control
for covariates such as age, menopause status, hypothyroid, and surgery effects, as well
as performing post-hoc analysis.
The study does not have a non-disease control group and did not have a pure
disease control group of radiotherapy only. Therefore, no inference can be made
regarding the impact of radiotherapy alone. The results of this study are not
representative of the general breast cancer population and cannot be compared to the
general population. Participants in this study self-selected, therefore self-selection bias
is a concern. There is potential that some individuals did not participate because they
predetermined they would not qualify.
There is a tendency for breast cancer studies to have samples of middle class,
white women. Fifteen out of the sixteen participants indicated they were white.
According to the Institute of Medicine (IOM, 2010) only 3-5% of individuals diagnosed
with cancer enroll in clinical trials. Through a systematic review covering 304 peerreviewed publications from 2001-2010, over 80% of the participants were white
(Kwiatkowski, Coe, Bailar & Swanson, 2013).
Individuals with diverse backgrounds did not volunteer to participate in this
study. Recruitment in the city of Harrisburg and Baltimore, as well as through a national
organization did not result in an increase of diversity in the sample. This study
attempted to address the bias of recruiting through social media by also recruiting
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through oncology clinics and providing non-Internet users an alternative to participate
with paper surveys. No requests for paper surveys were received.
This study did not directly measure cognition through standardized, objective
neurological testing. Additionally, functional performance was not measured on a
standardized observational scale. The study relied entirely on self-report measures
which may be impacted by recall bias, social desirability and errors in self-observation
(National Collaborating Centre for Primary Care). Additionally, no conclusions about the
causality of cognitive and functional changes may be drawn due to the lack of a pretreatment cognitive assessment. The optimal design would include pre-surgical
cognitive assessment and pre-chemotherapy assessment with follow-ups (Wefel et al.,
2011).
Implications for Occupational Therapy
Occupational therapists have a strong tradition in the provision of cognitive
rehabilitation services for developmental, traumatic, psychological and
neurodegenerative conditions. An assumption is made that these skills will carry over to
the cancer population and to some extent they do. However, occupational therapists
must understand not only the etiology of the cognitive impairments but also the
manifestations in the performance of occupations. This study is a beginning point for
understanding some of the cognitive and functional performance difficulties that may
occur after treatment for breast cancer. This study brings to light the complexity of
PBBCI. Higher levels of fatigue, depression and anxiety were all highly correlated with
lower levels of cognitive function, physical function and participation in social roles.
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In the clinic, occupational therapist are responsible for assessing occupational
performance. Many individuals with breast cancer receive occupational referrals as a
result of lymphedema. Occupational therapists need to look beyond the physical
performance and remediation of lymphedema symptoms and screen for changes in
cognition, as well as the presence of anxiety, depression and fatigue. These areas can
quickly be screened through self-report with the PROMIS® scales.
The top-down approach of occupational therapy views the client in a holistic
manner and provides treatment with a broad based focus on the performance of
personally meaningful activities. Occupational therapists can assist individuals in the
period following the conclusion of chemotherapy and radiotherapy treatment through the
instruction and implementation of energy conservation, pain management and
relaxation techniques, mindfulness training, developing compensatory strategies to
cope with memory changes and cognitive behavioral therapy. Home based and
technology based delivery of occupational therapy and cognitive behavioral therapy are
beginning to emerge with successful outcomes (Cheng, Lim, Koh, & Tam, 2017;
Ferguson et al., 2016; Lyons, Erickson & Hegel, 2012; Morean, O’Dwyer, & Cherney,
2015). Additionally, group of researchers in Spain are currently recruiting for a
randomized trial examining the use of occupational therapy for supportive care using a
m-health approach (Lozano-Lozano et al., 2016).
Breast cancer survivors may be referred to occupational therapy for only
lymphedema treatment. It is the occupational therapists responsibility to thoroughly
assess occupational performance and to look at the impact changes in cognition,
anxiety, depression and fatigue may be having on their participation. The PROMIS®
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instruments offer a quick, standardized way to assess and measure change in these
factors. Additionally, they offer norms for easy comparison. The items on the
PROMIS® scales provide insight into areas that should be evaluated in greater depth.
Recently the American Occupational Therapy Association began promoting the
role of occupational therapy in oncology rehabilitation. Again this is primarily based in
the assumption that assessment and intervention will transfer from other areas of
practice. There is a paucity of occupational therapy specific research addressing
cognitive impairment within cancer rehabilitation. Recently published research reviews
published in the American Journal of Occupational Therapy (AJOT) are based on the
analysis of evidence from other disciplines (Baxter, Newman, Longpré, & Polo, 2017;
Hunter, Gibson, Arbesman & D’Amico, 2017a; Hunter, Gibson, Arbesman & D’Amico,
2017b). This study is a beginning point to better understanding the impact of PBCCI on
functional performance. Furthermore, no occupational therapy studies were located in a
recent search of currently funded NIH projects related to intervention for cognitive
impairment related to cancer.
The PROMIS® instruments used in this study were designed for both research
and clinical use and serve as a convenient method for gathering information on multiple
factors related to cognition and cancer. Occupational therapists can use these
instruments to screen clients and to measure changes over the course of treatment. In
fact, PROMIS® instruments are readily available in some of the major electronic
medical record systems.
In this sample, the ability to participate in social roles and activities was lower
than the average for a chronic illness enriched general US population. This is an area in
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which occupational therapists can provide intervention to improve participation. The
theoretical foundation for this study, the Model of Human Occupation, is focused on
understanding the performance of occupations by taking into account volition, habits
and performance capacity. From this study it may be hypothesized that depression and
anxiety may impact an individual’s volition. Performance capacity may be impacted by
cognitive and physical changes resulting from the disease process and associated
treatment.
Additionally, it is vital that occupational therapists work collaboratively with the
oncology team. The Conceptual Model of Chemotherapy-Related Changes in Cognitive
Function developed in the nursing field provides a framework for occupational therapists
to understand the complexity of factors that contribute to PBCCI. The model provides a
basic definition of functional performance. Occupational therapy models, such as
MOHO, provide a way to extend the model to reflect the functional trajectory of the
client with cancer.
Despite the attention that PBCCI is receiving in the research community, this
information does not appear to be changing clinical intervention for survivors. In a study
of over 2,000 breast cancer survivors in the US, 60% of the sample self-reported
cognitive problems (Buchanan, et al., 2015). Of these, 37% discussed these concerns
with their medical provide and a mere 15% of these individuals reported receiving any
type of treatment (Buchanan, et al., 2015). Survivors are not being referred to services
such as occupational therapy that address changes they are noticing in their cognition
and ability to perform everyday activities. Occupational therapy provides a unique and
holistic approach to the treatment of cognitive impairment with a focus on participation
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in meaningful occupations. As a profession, occupational therapists must advocate for
our role in the cognitive rehabilitation of cancer survivors.
Recommendations for Future Research
This study scratched the surface in understanding the connection of self-reported
cognitive impairment and its relationship to changes in functional performance. Further
research needs to better describe the impact of cancer treatment, not only as it
concerns changes in cognition but as a whole, on the participation in daily meaningful
occupations. The design of this study can be improved upon to provide one approach to
this end. First, a better design would be to enroll participants prior to beginning
treatment to provide a baseline for functional performance and cognition. The study
might also include additional comparison groups: a chemotherapy only group, a
chemotherapy and radiotherapy group, a radiotherapy only group and a hormone
therapy only group. The inclusion of standardized neurological assessments may also
strengthen the design. Objective neurological assessments would provide a way to
pinpoint specific deficit areas. For example, the Rivermead Behavioral Memory
Assessment would provide better information about the domains of memory that are
impaired and the extent of the impairment. Likewise, the Test of Everyday Attention can
provide more detail about deficits in attention. The sample size should be increased to
adequately power the study. Special attention should be paid to recruitment procedures
and methods for follow-up to limit attrition. This study followed participants for 6 months.
This is a very short period. A greater length of follow up is needed to understand the
long term impacts of cancer diagnosis and treatment on cognition and function.

88

This study depended on self-report measures. Other studies attempting to
measure cognition related to breast cancer treatment heavily relied on standardized
neuropsychological testing (Ahles, Root & Ryan, 2012). Standard neuropsychological
testing is heavily decontextualized from the demands of everyday living with testing
environments that remove all distractors (Nelson & Suls, 2013; Hutchinson, et al. 2011).
This poses a problem, as the impact of PBCCI on activities and participation has not
been measured with standardized, valid and reliable assessments. Research utilizing
an ecological approach to the evaluation of cognition is needed. Ecological
assessments are designed to measure cognitive function within the demands of real life
living. Occupational therapists often use ecological approaches to evaluation and are
well suited to perform research that would examine the utility of an ecological approach
in assessing cognitive impairments associated with cancer treatment.
Additionally, well designed studies are needed to examine the efficacy of
occupational intervention for cognitive impairment. Studies are needed to compare
occupational intervention to other interventions and also in combination with other
treatments, in order to provide cancer survivors with the best options.
This study excluded participants with metastatic breast cancer and several
women expressed disappointment about not being able to participate. They too, face
cognitive impairments that impact their ability to do the things they want to do. Research
is needed in understanding the unique changes in cognition and activities and
participation of this population. As current treatments are extending the life
expectancies of individuals living with Stage VI cancer, these people want to continue

89

doing things they like to do. Occupational therapy has the potential to provide
interventions that will improve the quality of life for these individuals.
Conclusion
When people complete cancer treatment they are forced into a life transition.
This follows a period in which medical appointments, surgeries, invasive radiation or
chemotherapy treatments and recovery periods have dominated their days. The big
question for survivors is “What’s next?” or “How do I get back to normal?” There are no
guides for this transition and little support is provided from the medical establishment.
Survivors may go from one day to the next wondering when they will feel like
themselves again. As survivors transition back into fuller levels of participation, the after
effects of treatment become more visible. Perhaps when the car keys were misplaced
before the cancer diagnosis it was viewed as the temporary absent-mindedness of a
busy person. After cancer such a miscue may be viewed as a symptom of the disease
or a result of invasive treatment and put in a category with forgetting names and
appointments or having trouble doing calculations. It is difficult to determine if selfreports are the result of changes in brain function or if they are the result of heightened
awareness and a desire to live as one recalled living before cancer. In either scenario,
occupational therapy intervention can facilitate increased participation and engagement
in occupations for cancer survivors.
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TITLE: The Impact of Chemotherapy and Radiotherapy for Breast Cancer on
Cognition and Functional Performance: A Comparative Analysis of Survey Data
taken at Three Time Points Post-Treatment
VCU IRB PROTOCOL NUMBER: HM20006120
INVESTIGATOR: Lynwood Gentry, PhD
If any information contained in this consent form is not clear or you have any questions, please
contact the study staff, by phone or email using the contact information at the end of this
document, to explain any information that you do not fully understand. You may take time to
think about or discuss this consent form with family or friends before making your decision.
When you are ready to decide return to this website to continue.
PURPOSE OF THE STUDY
The purpose of this research study is to find out how cognition and the ability to do everyday
activities changes in the 6 months after the completion of treatment for breast cancer.
You are being asked to participate in this study because you are nearing the end of
chemotherapy or radiotherapy for breast cancer
DESCRIPTION OF THE STUDY AND YOUR INVOLVEMENT
If you decide to be in this research study, you will be asked to indicate that you consent to
participate in the research by checking a box after you have had all your questions answered
and understand what you will need to do.
Once you submit your consent form, you will be directed to an eligibility questionnaire. This
questionnaire will ask you questions about your breast cancer diagnosis and treatment, and
your medical history. If you are eligible to continue in the study you will be redirected to the
study surveys about your daily activities and cognitive function.
If you are eligible for this study you will be asked to complete online surveys three different
times. The first time you complete the surveys will be about two weeks after you complete
either chemotherapy or radiation. Then you will complete the same surveys 3 and 6 months
later. You will receive an email or text reminders to keep on schedule. The survey will ask you
demographic and medical history questions, as well as questions about your general health,
activities that you are able to do and how well you feel you do these activities, your attention
and memory, and concerns that you have
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such as feeling nervous or fearful. The surveys will take 15-30 minutes to complete. During the
first survey you will also be asked to refer a caregiver or someone close to you that you see on
a regular basis, and is over 18 years of age, to participate by providing an email address or
phone number (text or voice) for that person. The caregiver will be asked similar questions
about how they observe your ability to do daily activities. If you do not have a caregiver to
refer or do not want to refer a caregiver you will still be able to participate in the study.
RISKS AND DISCOMFORTS
Sometimes thinking about these subjects causes people to become upset. Several questions will
ask about feeling depressed or anxious. You do not have answer any questions that you do not
want to and you may leave the study at any time. If you become upset, you may contact the
study staff with the information provided at the end of this document and you will be given the
name of a support group to contact so you can get help in dealing with these issues.
USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION
Authority to Request Protected Health Information
The following people and/or groups may request my Protected Health Information:
•
•
•

Principal Investigator and Research Staff
Institutional Review Boards
Government/HealthAgencies

Authority to Release Protected Health Information
The VCU Health System (VCUHS) may release the information identified in this authorization
from my medical records and provide this information to:
•
•
•
•
•

•
•
•
•

Health Care Providers at the VCUHS
Study Sponsor
Data Coordinators
Data Safety Monitoring Boards
Others as Required by Law

Principal Investigator and Research Staff
Research Collaborators
Institutional Review Boards
Government/HealthAgencies

Once your health information has been disclosed to anyone outside of this study, the
information may no longer be protected under this authorization.
Type of Information that may be Released
The following types of information may be used for the conduct of this research:
Complete health record

Laboratory test results

Diagnosis & treatment
codes

Consultation reports
X-ray reports
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Discharge summary

Progress notes
X-ray films /
i

Photographs, videotapes
Complete billing record
Itemized bill
Information about drug or alcohol abuse
Information about Hepatitis B or C tests
Information about psychiatric care
Information about sexually transmitted
diseases
Other (specify):

Expiration of This Authorization
This authorization will expire when the research study is closed, or there is no
need to review, analyze and consider the data generated by the research project,
whichever is later.
This research study involves the use of a Data or Tissue Repository (bank) and
will never expire.
Other (specify):
Right to Revoke Authorization and Re-disclosure
You may change your mind and revoke (take back) the right to use your protected health
information at any time. Even if you revoke this Authorization, the researchers may still use or
disclose health information they have already collected about you for this study. If you revoke
this Authorization you may no longer be allowed to participate in the research study. To
revoke this Authorization, you may write, email or text message the Principal Investigator with
your request.
BENEFITS TO YOU AND OTHERS
You may not get any direct benefit from this study, but, the information we learn from people
in this study may help us design treatments that will help individuals transition out of
treatment and back to full living.
COSTS
There are no costs for participating in this study other than the time you will spend filling out
questionnaires.
PAYMENT FOR PARTICIPATION
If you are eligible to participate in this study, you will receive an electronic $10.00 gift certificate
to Amazon.com or Starbucks, at an email address you provide, once you have completed the first
survey. You will also have the option to donate $10 to the Young Survival Coalition if you do not
want a gift certificate.
ALTERNATIVES
If you would like to complete this study with paper surveys please contact the primary
investigator, Ann Marie Potter, listed below. You may call, email or text message. You will be
asked to provide a mailing address where you would like to receive the consent form and
surveys. You will first receive the consent form and eligibility survey. Once
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your completed consent forms are received and you are determined eligible, the study surveys
will arrive by mail. This will be about 2 weeks after you complete radiation or chemotherapy,
and again 3 and 6 months later.
CONFIDENTIALITY
Potentially identifiable information about you will consist of your name, birth date, email
address, home address, breast cancer diagnosis, and survey data. Data is being collected only
for research purposes.
Your data will be identified by a computer assigned ID numbers, not names, and stored
separately from research data in a password protected file. All personal identifying information
will be kept in separate password protected files and these files will be deleted in 5 years.
Access to all data will be limited to study personnel. If you are not eligible for the study your
data will be deleted prior to the data analysis phase of the project.
We will not tell anyone the answers you give us; however, information from the study may
be looked at or copied for research or legal purposes by Virginia Commonwealth University.
Personal information about you might be shared with or copied by authorized officials of the
Department of Health and Human Services or other federal regulatory bodies.
What we find from this study may be presented at meetings or published in papers, but your
name will not ever be used in these presentations or papers.
VOLUNTARY PARTICIPATION AND WITHDRAWAL
You do not have to participate in this study. Your decision not to take part will involve no
penalty or loss of benefits to which you are otherwise entitled. If you choose to participate,
you may stop at any time without any penalty. Your decision to withdraw will involve no
penalty or loss of benefits to which you are otherwise entitled. You may also choose not to
answer particular questions that are asked in the study.
Your participation in this study may be stopped at any time by the study staff without your
consent. The reasons might include:
• the study staff thinks it necessary for your health or safety;
• you have not followed study instructions;
• administrative reasons require your withdrawal.
QUESTIONS
If you have any questions, complaints, or concerns about your participation in this research,
contact:
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Ann Marie Potter, MA, OTR/L - Doctoral Candidate, Researcher Email: pottera2@vcu.edu
Phone/Text: 717-298-7005 Mail: Elizabethtown College,
One Alpha Drive, Occupational Therapy Department,
Elizabethtown, PA 17022
and/or
Tony Gentry, PhD. – Advisor Email: logentry@vcu.edu Phone: 804-828-3397
Mail: Department of Occupational Therapy 730 East Broad Street
P.O. Box 980008
Richmond, Virginia 23298-0008
The researcher/study staff named above is the best person(s) to call for questions about your
participation in this study.
If you have any general questions about your rights as a participant in this or any other
research, you may contact:
Office of Research
Virginia Commonwealth University 800 East Leigh
Street, Suite 3000
P.O. Box 980568 Richmond, VA 23298
Telephone: (804) 827-2157
Contact this number to ask general questions, to obtain information or offer input, and to
express concerns or complaints about research. You may also call this number if you cannot
reach the research team or if you wish to talk with someone else. General information about
participation in research studies can also be found at
http://www.research.vcu.edu/irb/volunteers.htm.
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Demographics
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Appendix C

PROMIS® Instruments
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Appendix D

Related Recruitment Documents
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Ann Marie Potter [ampotter.otr@gmail.com]
Actions
To:
Potter, Ann M

---------- Forwarded message ---------From: Stacie Jeter <e>
Date: Thu, May 21, 2015 at 4:33 PM
Subject: RE: Follow up from Thursday
To: Ann Marie Potter <ampotter.otr@gmail.com>

Sunday, July 05, 2015 3:58 PM

Ann Marie, I wanted to follow-up with you as I was finally able to connect with one of the folks
in our IRB. If not to have the study approved by our IRB here at Hopkins, we are not allowed to
post information in our clinic about the study or include the study in a list of “our” clinical trials
on our websites/handouts; however, our medical oncologists could hand a flier to potentially
eligible patients when they see them in clinic that gives them info about the study and invites
them to contact you directly. I think that this should still work/help – and save the regulatory
effort. Good news! Stacie
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Hi Ann Marie!

I reviewed the submission for your research project “The Relationship between Post Breast
Cancer Cognitive Impairment and Function.” YSC would be glad to post about your study on
social media to aid in your recruitment efforts. Since it looks like participants must be in the
Pennsylvania/Baltimore area, I am thinking that our NorthEast Regional Facebook page would
be the best place to advertise, but we can also post on the national YSC Facebook page too and
Twitter. When your study is IRB approved and you’re ready to recruit patients, please send me
your proposed text for posting.

I hope you are well. Are you going to BCY2?

Best,

Michelle

Michelle Esser
Program Manager, Research and Advocacy • Survivor
YOUNG SURVIVAL COALITION
Young women facing breast cancer together.

Work days: Monday through Thursday
c 215.588.5572 I youngsurvival.org
Like us on Facebook

and Follow us on Twitter and Instagram
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List of support groups contacted
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List of support groups contacted

Pink Ribbon Friends
Cancer Caring Center
Pink Ribbon Girls
The Small Group Ministry for Breast Cancer Support
P.I.N.K Partners York
Celebrating Hope in Cancer Survivors (CHICS)
ABC Breast Cancer Support Group (YWCA of Carlisle)
Hanover Area Breast Cancer Support Group
ENCORE (YWCA of Allentown) Breast Cancer Recovery Program
Cancer Support Community of the Greater Lehigh Valley
Breast Cancer Support Services of Berks
Breast Friends of PA Breakfast Club
The Cancer Support of Greater Philadelphia
The Healing Foundation of Bucks County
Linked By Pink (Erie)
Looking Ahead Breast Cancer Support Group (Meadville)
Warren County Women's Cancer Support Group
Mercer County Breast Cancer Support Group
Our Clubhouse (Pittsburgh)
Pink Steel Dragon
Butler Breast and Women's Cancer Support Group
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Appendix F

Confidence Intervals Tables
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Table F1
Chemotherapy + Radiation group 95% Confidence Intervals for Correlations among TScore Changes over the Six Months Post Treatment
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Table F1 continued
Chemotherapy + Radiation group 95% Confidence Intervals for Correlations among TScore Changes over the Six Months Post Treatment
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Table F2
Chemotherapy + Radiation group 95% Confidence Intervals for Correlations among TScore Changes over the Six Months Post Treatment
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Table F2 continued
Chemotherapy + Radiation group 95% Confidence Intervals for Correlations among TScore Changes over the Six Months Post Treatment
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She graduated from Vernon Township High School, Vernon, New Jersey in 1985. She
received her Bachelor of Arts in Psychology from Luther College, Decorah, Iowa in
1989. She received a Master of Arts in Occupational Therapy from University of
Southern California, Los Angeles, California in 1995. She worked as an occupational
therapist specializing in Spinal Cord Injury at Rancho Los Amigos Medical Center,
Downey, California from 1992-1995. From 1997- 2002, she was a Clinical Assistant
Professor at Florida International University, Miami, Florida in the Occupational Therapy
Department. In 2002, she took a position as a lecturer in the Occupational Therapy
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